Index to Volume 26

Author Index

- A -

Abarca J: see Patanwala AE, et al, 896
Abidi MH: see Said A, et al, 289
Abu-Laban RB: see Samoy LJ, et al, 1578
ACCP: 2006 Annual Meeting Abstracts and Index of Authors, 1535
ACCP: 2006 Spring Practice and Research Forum Abstracts and Index of Authors, 734
ACCP: Critical Pathways: The Role of Pharmacy Today and Tomorrow, 1358
ACCP, Fagan SC, Touchette D, Smith JA, Sowinski KM, Dolovich L, Olson KL, Cheang KI, Kolesar JM, Crismon ML: The State of Science and Research in Clinical Pharmacy, 1027
ACCP, Murphy JE, Nappi JM, Bosso JA, Saseen JJ, Hemstreet BA, Halloran MA, Spinler SA, Welty TE: American College of Clinical Pharmacy's Vision of the Future: Postgraduate Pharmacy Residency Training as a Prerequisite for Direct Patient Care Practice, 722
ACCP, Saseen JJ, Grady SE, Hansen LB, Hodges BM, Kovacs SJ, Martinez LD, Murphy JE, Page II RL, Reichert MG, Stringer KA, Taylor CT: Future Clinical Pharmacy Practitioners Should Be Board-Certified Specialists, 1816
Ackerman BH: see Varghese SP, et al, 699
Ahmed S: see Qureshi AI, et al, 493
Ahmet AH: see Lam C, et al, 1811
Akers WS: see Oh JJ, et al, 569
Akers WS: see Weant KA, et al, 1616
Akins RL, Haase MR, Levy EN: Pharmacokinetics of Daptomycin in a Critically Ill Adolescent with Vancomycin-Resistant Enterococcal Endocarditis, 694
Albert M: see Darveau M, et al, 1587
Albertson TE: see Albertson TE, et al, 1091
Alexander B: see Kurpius MP, et al, 505
Alexander SL, Ernst FR: Use of Drotrecogin alfa (activated) in Older Patients with Severe Sepsis, 533
Alfaro RM: see Robertson SM, et al, 1051
Ali A: see DeMonaco HJ, et al, 323
Altshuler M: see Studdiford J, et al, 1658
Ambrose PG: Monte Carlo Simulation in the Evaluation of Susceptibility Breakpoints: Predicting the Future: Insights from the Society of Infectious Diseases Pharmacists, 129
Anderson PL: see Kiser JJ, et al, 511
Anderson RC, Bussey HI: Retrievable and Permanent Inferior Vena Cava Filters: Selected Considerations, 1595
Andrus MR: see Clark DB, et al, 269
Anger KE, Szumita PM: Barriers to Glucose Control in the Intensive Care Unit, 214
Aparasu RR: see Mort JR, et al, 1307
Aquilina C: see Tavassoli N, et al, 154
Arant CB: see Welder GJ, et al, 1794
Arant CB: see Zineh I, et al, 1572
Arant CB: see Zineh I, et al, 333
Armstrong EP: see Ko Y, et al, 1694
Arnold LM, Crouch MA, Carroll NV, Oinonen MJ: Outcomes Associated with Vasoactive Therapy in Patients with Acute Decompensated Heart Failure, 1078
Aryana A: see Maciejewski S, et al, 889
Asano A, Kobayashi J, Murase Y, Nohara A, Kawashiri M, Inazu A, Shimizu M, Mabuchi H: Effects of Fenofibrate Therapy on Plasma Ubiquinol-10 and Ubiquinone-10 Levels in Japanese Patients with Hyperlipidemia and Type 2 Diabetes Mellitus, 447
Aston JL, Lodolce AE, Shapiro NL: Interaction Between Warfarin and Cranberry Juice, 1314
Ataga KI, Orringer EP, Styles L, Vichinsky EP, Swerdlow P, Davis GA, DeSimone PA, Stocker JW: Dose-Escalation Study of ICA-17043 in Patients with Sickle Cell Disease, 1557
Awad EA: see Jann MW, et al, 627

- B -

Badawi O: Possible Effect of Thyroid Function on Anticoagulant Response to Unfractionated Heparin, 285
Badell ML, Ramin SM, Smith JA: Treatment Options for Nausea and Vomiting During Pregnancy, 1273
Badillo R: see Lewis TV, et al, 403
Baer RK: see Mort JR, et al, 1307
Bagheri H: see Tavassoli N, et al, 154
Balen RM: see Samoy LJ, et al, 1578
Barnes BJ, Gerst C, Smith JR, Terrell AR, Mullins ME: Osmol Gap as a Surrogate Marker for Serum Propylene Glycol Concentrations in Patients Receiving Lorazepam for Sedation, 23
Barnes BJ: see Moeller KE, et al, 445
Barrett JC: see Figg WD, et al, 759
Beal JM: see Stroup JS, et al, 689
Bednarczyk E: see Tomilo DL, et al, 341
Beitelshees AL, Zineh I, Yarandi HN, Pauly DF, Johnson JA: Discordant β-Blocker Effects on Clinic, Ambulatory, Resting, and Exercise Hemodynamics in Patients with Hypertension, 1247
Bélisle S: see Darveau M, et al, 1587
Benoff BA: see Strachan PM, et al, 578
Berenson CS: see Tomilo DL, et al, 341
Berger JR: see Wermeling DP, et al, 395
Berger PB: see Levine GN, et al, 1537
Berghoff JL: see Quinn JA, et al, 1410
Bernard J: see Tavassoli N, et al, 154
Bessler M: see Field JJ, et al, 1662

Beumer JH, Natale JJ, Lagattuta TF, Raptis A, Egorin MJ: Disposition of Imatinib and Its Metabolite CGP74588 in a Patient with Chronic Myelogenous Leukemia and Short-Bowel Syndrome, 903
Bhatt MS: see Hutcherson DA, et al, 242
Bianco TM: see Ito MK, et al, 939
Bilker WB: see Hennessy S, et al, 1342
Birkinshaw J: see Figg WD, et al, 759
Birtcher KK: see Ito MK, et al, 939
Blake K: Review of Guidelines and the Literature in the Treatment of Acute Bronchospasm in Asthma, 148S
Bleske BE: see Ito MK, et al, 939
Blinder MA: see Field JJ, et al, 1662
Boguk I: see Caron MD, et al, 1241
Bond CA, Raehl CL: Adverse Drug Reactions in United States Hospitals, 601
Bond CA, Raehl CL: Clinical and Economic Outcomes of Pharmacist-Managed Antiepileptic Drug Therapy, 1369
Bond CA, Raehl CL: Clinical Pharmacy Services, Pharmacy Staffing, and Adverse Drug Reactions in United States Hospitals, 735
Bonnet E: see Tavassoli N, et al, 154
Borok GM: see Bullano MF, et al, 469
Bosso JA: see ACCP, et al, 722
Bottorff M: Role of the Pharmacist, 227S
Bouthier F: see Laroche M-L, et al, 1041
Bouvy ML: see van der Elst ME, et al, 254
Bower A: see Bruce SP, et al, 1193
Boyd CJ: see Teter CJ, et al, 1501
Boyd ST: The Endocannabinoid System, 218S
Brixner DI: see Creekmore FM, et al, 1438
Brophy JM: see Etminan M, et al, 479
Brouillard JE, Terriff CM, Tofan A, Garrison MW: Antibiotic Selection and Resistance Issues with Fluoroquinolones and Doxycycline Against Bioterrorism Agents, 3
Bruce SP, Bower A, Hak E, Schwartz AH: Utilization of the Center for the Advancement of Pharmaceutical Education Educational Outcomes, Revised Version 2004: Report of the 2005 American College of Clinical Pharmacy Educational Affairs Committee, American College of Clinical Pharmacy, 1193
Bruner-England TE: see Morris AB, et al, 483
Bruno-Murtha LA: see Thai XC, et al, 1183
Bullano MF, Wertz DA, Yang GW, Kamat S, Borok GM, Gandhi S, McDonough KL, Willey VJ: Effect of Rosuvastatin Compared with Other Statins on Lipid Levels and National Cholesterol Education Program Goal Attainment for Low-Density Lipoprotein Cholesterol in a Usual Care Setting, 469
Bullock T: see John EJ, et al, 1511
Bungard TJ: see George-Phillips KL, et al, 1479
Bussey HI: see Anderson RC, et al, 1595
Button-Neumann B: see John EJ, et al, 1511
Byrd DC: see Clark DB, et al, 269

- C -

Calis K: see Horne III MK, et al, 1262
Callen EC, Church CO: Plasmodium falciparum Malaria Associated with Mefloquine Failure in Gambia, 1526
Canionero M: see Garcia S, et al, 440
Cannon BC: see Moffett BS, et al, 1687
Caron MD, Dore DD, Min B, Kluger J, Boguk I, White CM: Electrocardiographic and Blood Pressure Effects of the Ephedra-Containing TrimSpa Thermogenic Herbal Compound in Healthy Volunteers, 1241
Carroll NV: see Arnold LM, et al, 1078
Carver PL: see Saad AH, et al, 1730
Cavanaugh SE: see Scheife RT, et al, 151
Cawley MJ, Lipka O: Intravenous Linezolid Administered Orally: A Novel Desensitization Strategy, 563
Cecil EJ: see Straley CM, et al, 435
Chan L-N: see Lee LS, et al, 44
Chang C-M, Lee H-C, Lee N-Y, Huang G-C, Lee I-W, Ko W-C: Cefotaxime-Ciprofloxacin Combination Therapy for Nontyphoid Salmonella Bacteremia and Paravertebral Abscess After Failure of Monotherapy, 1671
Charmes J-P: see Laroche M-L, et al, 1041
Chavalitanonda N: see Ward CT, et al, 1175
Cheang KI: see ACCP, et al, 1027
Chegini N: see Zineh I, et al, 333
Chen A: see DiCenzo R, et al, 1255
Chen JJ: see Obering CD, et al, 840
Chester EA: see Raebel MA, et al, 619
Cheung RJ: see Ito MK, et al, 939
Chicella MF: see Storms LE, et al, 410
Childs R: see Horne III MK, et al, 1262
Chindalore VL: see Divittorio G, et al, 104
Chiquette E: see Triplitt C, et al, 360
Chiu Y-Y: see True AL, et al, 1679
Chong PH: see Ito MK, et al, 939
Chonlahan J, Halloran MA, Hammonds A: Leflunomide and Warfarin Interaction: Case Report and Review of the Literature, 868
Chow MSS: see Yin OQP, et al, 790
Chumney ECG: see Whitley HP, et al, 682
Church CO: see Callen EC, et al, 1526
Cienki JJ: see Wolowich WR, et al, 1268
Clark BM, Kotti GH, Shah AD, Conger NG: Severe Serum Sickness Reaction to Oral and Intramuscular Penicillin, 705
Clark DB, Andrus MR, Byrd DC: Drug Interactions Between Linezolid and Selective Serotonin Reuptake Inhibitors: Case Report Involving Sertraline and Review of the Literature, 269
Clunie S: see Moffett BS, et al, 277
Cohen DJ: see Levine GN, et al, 1537
Cole J: see Mathews S, et al, 1446
Cole JA, Norman H, Weatherby LB, Walker AM: Drug Copayment and Adherence in Chronic Heart Failure: Effect on Cost and Outcomes, 1157
Coleman CI: see Gillespie EL, et al, 499
Coleman CI: see Sander S, et al, 51
Coley KC: see Corman SL, et al, 1433

Colombo CS: see Quinn JA, et al, 1410
Conger NG: see Clark BM, et al, 705
Coons JC: see Seybert AL, et al, 229
Corman SL, Coley KC, Schonder KS: Effect of Long-term Tacrolimus Immunosuppression on Renal Function in Liver Transplant Recipients, 1433
Craddock D: see McCall KL, et al, 1297
Craig DS: Reduction of High-Risk Polypharmacy Drug Combinations in Patients in a Managed Care Setting, 886
Cranford JA: see Teter CJ, et al, 1501
Crank CW: see Segret JA, et al, 347
Creekmore FM, Oderda GM, Pendleton RC, Brixner DI: Incidence and Economic Implications of Heparin-Induced Thrombocytopenia in Medical Patients Receiving Prophylaxis for Venous Thromboembolism, 1438
Crismon ML: see ACCP, et al, 1027
Crouch MA: see Arnold LM, et al, 1078
Crouch MA: see Miano TA, et al, 828
Crouch MA: see Summers KM, et al, 609
Cubeddu LX, Seamon MJ: Statin Withdrawal: Clinical Implications and Molecular Mechanisms, 1288
Currie J: see John EJ, et al, 1511

- D -

Dager WE, King JH, Regalia RC, Williamson D, Gosselin RC, White RH, Tharratt RS, Albertson TE: Reversal of Elevated International Normalized Ratios and Bleeding with Low-Dose Recombinant Activated Factor VII in Patients Receiving Warfarin, 1091
Dager WE, Sanoski CA, Wiggins BS, Tisdale JE: Pharmacotherapy Considerations in Advanced Cardiac Life Support, 1703
Dang CH, Durkalski VL, Nappi JM: Evaluation of Treatment with Direct Thrombin Inhibitors in Patients with Heparin-Induced Thrombocytopenia, 461
Darveau M, Notebaert E, Denault AY, Williamson DR, Albert M, Bélisle S, Lachaine J: Erythropoietic Response to Two Epoetin alfa Regimens in Critically Ill Patients: A Pilot Study, 1587
Dasta JF, Jacobi J, Sesti A-M, McLaughlin TP: Addition of Dexmedetomidine to Standard Sedation Regimens After Cardiac Surgery: An Outcomes Analysis, 798
Davis GA: see Ataga KI, et al, 1557
de Blaey CJ: see van der Elst ME, et al, 254
de Boer A: see van der Elst ME, et al, 254
de Leon J: see Villanueva N, et al, 1352
DeBella AE: see Zineh I, et al, 1572
DeBella AE: see Zineh I, et al, 333
Delate T: see McConnell KJ, et al, 1333
Delpierre C: see Tavassoli N, et al, 154
DeMasi RA: see True AL, et al, 1679
DeMonaco HJ, Ali A, von Hippel E: The Major Role of Clinicians in the Discovery of Off-Label Drug Therapies, 323
Denault AY: see Darveau M, et al, 1587
Denfield S: see Moffett BS, et al, 277
DePestel DD: see Saad AH, et al, 1730
DeSimone PA: see Ataga KI, et al, 1557
Diaz FJ: see Villanueva N, et al, 1352
Dice JE: see Storms LE, et al, 410
DiCenzo R, Frerichs V, Larppanichpoonphol P, Predko L, Chen A, Reichman R, Morris M: Effect of Quercetin on the Plasma and Intracellular Concentrations of Saquinavir in Healthy Adults, 1255
Dieterle N: see Said A, et al, 289
Difrancesco R: see Tomilo DL, et al, 341
Divittorio G, Jackson KL, Chindalore VL, Welker W, Walker JB: Examining the Relationship Between Bone Mineral Density and Fracture Risk Reduction During Pharmacologic Treatment of Osteoporosis, 104
Dobesh PP: see Stacy ZA, et al, 919
Dodds Ashley ES: Treatment Options for Invasive Fungal Infections, 55S
Dolovich L: see ACCP, et al, 1027
Doraiswamy PM: see Szarfman A, et al, 748
Dore DD: see Caron MD, et al, 1241
Dorsch MP, Dunn SP: Antiplatelet Drug Resistance: Almost Ready for Prime Time, 1201
Dorsch MP, Montague D, Rodgers JE, Patterson C: Abciximab-Associated Thrombocytopenia After Previous Tirofiban-Related Thrombocytopenia, 423
Dorsch MP, Rodgers JE: Nesiritide: Harmful or Harmless?, 1465
Doucette W: see John EJ, et al, 1511
Dreyer WJ: see Moffett BS, et al, 277
Drusano GL: see Lodise TP, et al, 1320
Dumo PA, Kielbasa LA: Successful Anticoagulation and Continuation of Tramadol Therapy in the Setting of a Tramadol-Warfarin Interaction, 1654
Dunn L: see Figg WD, et al, 759
Dunn SP: see Dorsch MP, et al, 1201
Dupuis LL, Taddio A, Kerr EN, Kelly A, MacKeigan L: Development and Validation of the Pediatric Nausea Assessment Tool for Use in Children Receiving Antineoplastic Agents, 1221
Dupuis LL, Taylor T, Saunders EF: Disposition of Two Oral Formulations of Cyclosporine in Pediatric Patients Receiving Hematopoietic Stem Cell Transplants, 15
Durkalski VL: see Dang CH, et al, 461
Durr EA: see Shapiro NL, et al, 1806

- E -

Eberhardt E: see Tomilo DL, et al, 341
Edwards K: see McCall KL, et al, 1297
Edwards KL: see Irons BK, et al, 168
Edwards RF: see Hammons KB, et al, 1165
Egorin MJ: see Beumer JH, et al, 903
Ehret MJ, Levin GM: Long-term Use of Atypical Antipsychotics in Bipolar Disorder, 1134
Eiland LS: see Townsend KA, et al, 95
Elewa HF, Hilali H, Hess DC, Machado LS, Fagan SC:

Minocycline for Short-Term Neuroprotection, 515
Ensom MHH: see Koleba T, et al, 813
Ensom MHH: see Ting LSL, et al, 1232
Ernst FR: see Alexander SL, et al, 533
Ernst ME: see Steffensmeier JJG, et al, 162
Erstad BL: see Patanwala AE, et al, 896
Etminan M, Zhang B, FitzGerald M, Brophy JM: Do Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Decrease the Risk of Hospitalization Secondary to Community-Acquired Pneumonia? A Nested Case-Control Study, 479

- F -

Fagan SC: see ACCP, et al, 1027
Fagan SC: see Elewa HF, et al, 515
Falcon RW: see Kakuda TN, et al, 1060
Falloon J: see Robertson SM, et al, 1051
Faneuf M: see Hutcherson DA, et al, 242
Fardoun RZ: Carvedilol versus Cardioselective β-Blockers for the Treatment of Hypertension in Patients with Type 2 Diabetes Mellitus, 1491
Farris K: see John EJ, et al, 1511
Ferguson R: see Qureshi AI, et al, 493
Fermo JD: see Lee NJ, et al, 583
Fermo JD: see Whitley HP, et al, 682
Field JJ, Giannone L, Bessler M, Blinder MA: Immunosuppressive Therapy for Acute Porphyria: Safety and Efficacy in a Patient with Bone Marrow Failure, 1662
Figg WD, Dunn L, Liewehr DJ, Steinberg SM, Thurman PW, Barrett JC, Birkinshaw J: Scientific Collaboration Results in Higher Citation Rates of Published Articles, 759
Figg WD: see Parnes HL, et al, 1533
Finney MS: see Segret JA, et al, 347
Fish DN: see Kiser TH, et al, 452
FitzGerald M: see Etminan M, et al, 479
Fletcher CV: see Kiser JJ, et al, 511
Flynn JD: see Oh JJ, et al, 569
Flynn JF: see Weant KA, et al, 1616
Ford SM, Grabenstein JD: Pandemics, Avian Influenza A (H5N1), and a Strategy for Pharmacists, 312
Formentini E: see Robertson SM, et al, 1051
Franic DM, Jiang JZ: Potentially Inappropriate Drug Use and Health-Related Quality of Life in the Elderly, 768
Frazee LA: see Lowe JF, et al, 353
Frei-Lahr DA: see McDonnell AM, et al, 806
Frerichs V: see DiCenzo R, et al, 1255
Friedman RA: see Moffett BS, et al, 1687
Fruehauf JP, Kong KM: A Tale of Two Growth Factors, 443
Frye CB: Orchestrating the Growth of Pharmacy as a Clinical Profession—A Comment, 1047
Fujioka K: Metabolic Syndrome Treatment Strategies, 222S
Fuke DC: see Haines ST, et al, 32S
Fuke DC: see Rodgers PT, et al, 13S

- G -

Gaffney SM: Ranolazine, a Novel Agent for Chronic Stable Angina, 135
Galatti L, Polimeni G, Salvo F, Romani M, Sessa A, Spina E: Short-Term Memory Loss Associated with Rosuvastatin, 1190
Gallagher R: see Gillespie EL, et al, 499
Gallant JE: see Sabundayo BP, et al, 674
Gammon DC: see Hutcherson DA, et al, 242
Gandhi S: see Bullano MF, et al, 469
Garcia S, Canionero M, Lopes G: Dipyrone-Induced Granulocytopenia: A Case for Awareness, 440
Garner SS, Wiest DB, Stevens CE, Habib DM: Effect of Heliox on Albuterol Delivery by Metered-Dose Inhaler in Pediatric In Vitro Models of Mechanical Ventilation, 1396
Garnick JJ: see Said A, et al, 289
Garrison MW: see Brouillard JE, et al, 3
Garwood CL, Van Schepen KA, McDonough RP, Sullivan AL: Increased Thyroid-Stimulating Hormone Levels Associated with Concomitant Administration of Levothyroxine and Raloxifene, 881
Gentry EJ: see Tafreshi MJ, et al, 388
George-Phillips KL, Bungard TJ: Use of Low-Molecular-Weight Heparin to Bridge Therapy in Obese Patients and in Patients with Renal Dysfunction, 1479
Gerhard T, Zineh I, Winterstein AG, Hartzema AG: Pharmacoeconomic Modeling of Nesiritide versus Dobutamine for Decompensated Heart Failure, 34
Gerst C: see Barnes BJ, et al, 23
Gettig JP: Investigating the Potential Influence of Established Multiple-Choice Test-Taking Cues on Item Response in a Pharmacotherapy Board Certification Examination Preparatory Manual: A Pilot Study, 558
Giannone L: see Field JJ, et al, 1662
Gibbs L: see Mendez MN, et al, 61
Gillespie EL, White CM, Kluger J, Rancourt JA, Gallagher R, Coleman CI: Cost-Effectiveness of Amiodarone for Prophylaxis of Atrial Fibrillation After Cardiothoracic Surgery, 499
Goldberg N: see Ng JA, et al, 1023
Golightly LK, Jones MA, Hamamura DH, Stolpman NM, McDermott MT: Management of Diabetes Mellitus in Hospitalized Patients: Efficiency and Effectiveness of Sliding-Scale Insulin Therapy, 1421
Gomolin IH: see Lam S, et al ,1169
Gortney JS: see Huang V, et al, 1784
Gosselin RC: see Albertson TE, et al, 1091
Gouveia WA: Orchestrating the Growth of Pharmacy as a Clinical Profession, 1
Grabenstein JD: see Ford SM, et al, 312
Grady SE: see ACCP, et al, 1816
Greene RS: see Irons BK, et al, 168
Guay DRP: Ibandronate, an Experimental Intravenous Bisphosphonate for Osteoporosis, Bone Metastases, and Hypercalcemia of Malignancy, 655

Guglielmo BJ: see Mendez MN, et al, 61
Guilday RE: see Varghese SP, et al, 699
Gupta EK: see Ito MK, et al, 939
Gutierrez MA: see Stimmel GL, et al, 1608

- H -

Haase MR: see Akins RL, et al, 694
Habib DM: see Garner SS, et al, 1396
Hackman AM, Lackner TE: Pharmacotherapy for Idiopathic Pulmonary Arterial Hypertension During the Past 25 Years, 68
Hagemann TM: see Lewis TV, et al, 403
Hahn HJ: see Lee JY, et al, 1069
Haines ST, Fuke DC, Lender D, Rodgers PT, Sysko SK: Evaluating and Treating Cardiometabolic Risk Factors: A Case Discussion, 32S
Haines ST: Introduction: Addressing Cardiometabolic Risk, 1S
Haines ST: see Patterson SL, et al, 1518
Haith Jr LR: see Varghese SP, et al, 699
Hak E: see Bruce SP, et al, 1193
Hall PD: see McDonnell AM, et al, 806
Halloran MA: see ACCP, et al, 722
Halloran MA: see Chonlahan J, et al, 868
Halterman T: see John EJ, et al, 1511
Hamamura DH: see Golightly LK, et al, 1421
Hamilton J: see Lam C, et al, 1811
Hammonds A: see Chonlahan J, et al, 868
Hammons KB, Edwards RF, Rice III WY: Golf-Inhibiting Gynecomastia Associated with Atorvastatin Therapy, 1165
Hanevold CD: Acute Renal Failure During Lisinopril and Losartan Therapy for Proteinuria, 1348
Hanje AJ, Shamp JL, Thomas FB, Meis GM: Thalidomide-Induced Severe Hepatotoxicity, 1018
Hansen LB: see ACCP, et al, 1816
Haraway GD: see Stroup JS, et al, 689
Hardinger KL: Rabbit Antithymocyte Globulin Induction Therapy in Adult Renal Transplantation, 1771
Hardy AM: see McConnell KJ, et al, 1333
Hartz AJ: see Steffensmeier JJG, et al, 162
Hartzema AG: see Gerhard T, et al, 34
Have TRT: see Hennessy S, et al, 1342
Hayes LE: see Hummel MC, et al, 1667
Hayslip J: see McDonnell AM, et al, 806
Hemstreet BA, Page II RL: Sulfonamide Allergies and Outcomes Related to Use of Potentially Cross-Reactive Drugs in Hospitalized Patients, 551
Hemstreet BA: see ACCP, et al, 722
Hemstreet BA: see Vondracek SF, et al, 522
Hennessy S, Leonard CE, Yang W, Kimmel SE, Townsend RR, Wasserstein AG, Have TRT, Bilker WB: Effectiveness of a Two-Part Educational Intervention to Improve Hypertension Control: A Cluster-Randomized Trial, 1342
Herald N, Laliberte K: Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients with New York Heart Association Class II–IV Symptoms, 1203
Herriman MP: see Straley CM, et al, 435
Hershey LA: see Qureshi AI, et al, 493
Hess DC: see Elewa HF, et al, 515
Heuring TJ: see Micek ST, et al, 204
Hilali H: see Elewa HF, et al, 515
Hilleman DE: see Maciejewski S, et al, 889
Hodges BM: see ACCP, et al, 1816
Holdford DA: see Summers KM, et al, 609
Hollands JM: see Micek ST, et al, 204
Holtzman CW, Wiggins BS, Spinler SA: Role of P-glycoprotein in Statin Drug Interactions, 1601
Hon YY: see Jann MW, et al, 627
Hönemann D: see Kenealy MK, et al, 1205
Horne III MK, McCloskey DJ, Calis K, Wesley R, Childs R, Kasten-Sportes C: Use of Heparin versus Lepirudin Flushes to Prevent Withdrawal Occlusion of Central Venous Access Devices, 1262
Huang G-C: see Chang C-M, et al, 1671
Huang V, Gortney JS: Risk of Serotonin Syndrome with Concomitant Administration of Linezolid and Serotonin Agonists, 1784
Huckleberry Y: see Patanwala AE, et al, 896
Hummel MC, Morse BC, Hayes LE: Reactive Thrombocytosis Associated with Enoxaparin, 1667
Hunt JS: see Rozenfeld Y, et al, 1565
Hursting MJ: see Patterson SL, et al, 1518
Hutcherson DA, Gammon DC, Bhatt MS, Faneuf M: Reduced-Dose Rasburicase in the Treatment of Adults with Hyperuricemia Associated with Malignancy, 242

- I, J -

Ibrahim RB: see Said A, et al, 289
Inazu A: see Asano A, et al, 447
Irons BK, Greene RS, Mazzolini TA, Edwards KL, Sleeper RB: Implications of Rosiglitazone and Pioglitazone on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus, 168
Ito MK, Cheung RJ, Gupta EK, Birtcher KK, Chong PH, Bianco TM, Bleske BE: Key Articles, Guidelines, and Consensus Papers Relative to the Treatment of Dyslipidemias—2005, 939
Ito MK, Talbert RL, Tsimikas S: Statin-Associated Pleiotropy: Possible Beneficial Effects Beyond Cholesterol Reduction, 85S
Jackson KL: see Divittorio G, et al, 104
Jacobi J: see Dasta JF, et al, 798
Jacobi J: see Quinn JA, et al, 1410
Jacobs RA: see Mendez MN, et al, 61
Jain R, Osei K, Kupfer S, Perez AT, Zhang J: Long-term Safety of Pioglitazone versus Glyburide in Patients with Recently Diagnosed Type 2 Diabetes Mellitus, 1388
Jann MW, Hon YY, Shamsi SA, Zheng J, Awad EA, Spratlin V: Lack of Pharmacokinetic Interaction Between Lamotrigine and Olanzapine in Healthy Volunteers, 627
Jefferies JL: see Moffett BS, et al, 277
Jefferies JL: see Moffett BS, et al, 281
Jiang JZ: see Franic DM, et al, 768

Jick H, Kaye JA, Russmann S, Jick SS: Nonsteroidal Antiinflammatory Drugs and Acute Myocardial Infarction in Patients with No Major Risk Factors, 1379
Jick SS: see Jick H, et al, 1379
John EJ, Vavra T, Farris K, Currie J, Doucette W, Button-Neumann B, Osterhaus M, Kumbera P, Halterman T, Bullock T: Workplace-Based Cardiovascular Risk Management by Community Pharmacists: Impact on Blood Pressure, Lipid Levels, and Weight, 1511
Johnson JA: see Beitelshees AL, et al, 1247
Johnson JL, Loomis IB: A Case of Simvastatin-Associated Pancreatitis and Review of Statin-Associated Pancreatitis, 414
Jones MA: see Golightly LK, et al, 1421
Jorgenson D: see Langford BJ, et al, 260

- K -

Kakuda TN, Falcon RW: Effect of Food and Ranitidine on Saquinavir Pharmacokinetics and Gastric pH in Healthy Volunteers, 1060
Kamat S: see Bullano MF, et al, 469
Kamath V: see Takiya L, et al, 115
Kang-Birken SL, Prichard JG: Mycobacterium szulgai in a Patient with Advanced Acquired Immunodeficiency Syndrome: An Unusual Pathogen with Unusual Multidrug Resistance, 1646
Kasten-Sportes C: see Horne III MK, et al, 1262
Kawashiri M: see Asano A, et al, 447
Kaye JA: see Jick H, et al, 1379
Kelleher JA: see Raebel MA, et al, 619
Kelly A: see Dupuis LL, et al, 1221
Kelly HW: Introduction, 145S
Kelly HW: Risk versus Benefit Considerations for the β_2-Agonists, 164S
Kelly HW: The Role of Pharmacists in the Evolution of Health Care: An Open Forum Discussion, 200S
Kelly M: see Steffensmeier JJG, et al, 162
Kenealy MK, Prince HM, Hönemann D: Tumor Lysis Syndrome Early After Treatment with Bortezomib for Multiple Myeloma, 1205
Kerr EN: see Dupuis LL, et al, 1221
Kertesz NJ: see Moffett BS, et al, 1687
Kielbasa LA: see Dumo PA, et al, 1654
Kimmel SE: see Hennessy S, et al, 1342
King JH: see Albertson TE, et al, 1091
Kintzel PE, Michaud LB, Lange MK: Docetaxel-Associated Epiphora, 853
Kirmani JF: see Qureshi AI, et al, 493
Kiser JJ, Lichtenstein KA, Anderson PL, Fletcher CV: Effects of Esomeprazole on the Pharmacokinetics of Atazanavir and Fosamprenavir in a Patient with Human Immunodeficiency Virus Infection, 511
Kiser TH, Fish DN: Evaluation of Bivalirudin Treatment for Heparin-Induced Thrombocytopenia in Critically Ill Patients with Hepatic and/or Renal Dysfunction, 452
Klepser ME: Candida Resistance and Its Clinical Relevance, 68S
Klepser ME: see Staat DD, et al, 1207
Kluger J: see Caron MD, et al, 1241
Kluger J: see Gillespie EL, et al, 499
Knoderer CA, Knoderer HM, Turrentine MW, Kumar M: Lepirudin Anticoagulation for Heparin-Induced Thrombocytopenia After Cardiac Surgery in a Pediatric Patient, 709
Knoderer HM: see Knoderer CA, et al, 709
Knowles SR: see Lowe DO, et al, 1641
Ko W-C: see Chang C-M, et al, 1671
Ko Y, Malone DC, Armstrong EP: Pharmacoeconomic Evaluation of Antimuscarinic Agents for the Treatment of Overactive Bladder, 1694
Kobayashi J: see Asano A, et al, 447
Kolansky DM: see Peterman CM, et al, 1086
Koleba T, Ensom MHH: Pharmacokinetics of Intravenous Immunoglobulin: A Systematic Review, 813
Kolesar JM: see ACCP, et al, 1027
Kollef MH: see Micek ST, et al, 204
Kong KM: see Fruehauf JP, et al 443
Kotti GH: see Clark BM, et al, 705
Kovacs SJ: see ACCP, et al, 1816
Koval P: see Wittbrodt E, et al, 203S
Krantz MJ: Implications of Thiazolidinedione Use and Cardiovascular Risk: Is It All About the Sugar?, 1049
Kroenke K: see Morris AB, et al, 483
Krueger CD: see Shapiro NL, et al, 1806
Kumar M: see Knoderer CA, et al, 709
Kumbera P: see John EJ, et al, 1511
Kupfer S: see Jain R, et al, 1388
Kurpius MP, Alexander B: Rates of In Vivo Methylation of Desipramine and Nortriptyline, 505
Kwan D: see Langford BJ, et al, 260

- L -

Labau E: see Tavassoli N, et al, 154
Laberge P: see Nenciu LM, et al, 872
Lachaine J: see Darveau M, et al, 1587
Lackner TE: see Hackman AM, et al, 68
Lagattuta TF: see Beumer JH, et al, 903
LaGrange K: see Teter CJ, et al, 1501
Laliberte K: see Herald N, et al, 1203
Lam C, Tjon J, Hamilton J, Ahmet AH: Recurrent Anaphylaxis Associated with Gonadotropin-Releasing Hormone Analogs: Case Report and Review of the Literature, 1811
Lam S, Gomolin IH: Cefepime Neurotoxicity: Case Report, Pharmacokinetic Considerations, and Literature Review, 1169
LaMonte MP: see Patterson SL, et al, 1518
Langan SJ: see Sabundayo BP, et al, 674
Lange MK: see Kintzel PE, et al, 853
Langford BJ, Jorgenson D, Kwan D, Papoushek C: Implementation of a Self-Administered Questionnaire to Identify Patients at Risk for Medication-Related Problems in a Family Health Center, 260
Laroche M-L, Charmes J-P, Marcheix A, Bouthier F, Merle L: Estimation of Glomerular Filtration Rate

in the Elderly: Cockcroft-Gault Formula versus Modification of Diet in Renal Disease Formula, 1041
Larppanichpoonphol P: see DiCenzo R, et al, 1255
Lau S-K: see Yin OQP, et al, 790
Le J, Lieberman JM: Management of Community-Associated Methicillin-Resistant Staphylococcus aureus Infections in Children, 1758
Leclerc JR: see Rubeiz GJ, et al, 428
Lee H-C: see Chang C-M, et al, 1671
Lee I-W: see Chang C-M, et al, 1671
Lee JY, Hahn HJ, Son IJ, Suh KS, Yi NJ, Oh JM, Shin WG: Factors Affecting the Apparent Clearance of Tacrolimus in Korean Adult Liver Transplant Recipients, 1069
Lee LS, Chan L-N: Evaluation of a Sex-Based Difference in the Pharmacokinetics of Digoxin, 44
Lee NJ, Fermo JD: Warfarin and Royal Jelly Interaction, 583
Lee N-Y: see Chang C-M, et al, 1671
Lee P-Y: see Wang Y-CL, et al, 143
Leighton JA: see Wells CD, et al, 1802
Lender D, Sysko SK: The Metabolic Syndrome and Cardiometabolic Risk: Scope of the Problem and Current Standard of Care, 3S
Lender D: see Haines ST, et al, 32S
Lenz KL: see McDonnell AM, et al, 806
Leonard CE: see Hennessy S, et al, 1342
Letendre DE: Against the Wind, 597
Levin GM: see Ehret MJ, et al, 1134
Levine GN, Berger PB, Cohen DJ, Maree AO, Rosenfield K, Wiggins BS, Spinler SA: Newer Pharmacotherapy in Patients Undergoing Percutaneous Coronary Interventions: A Guide for Pharmacists and Other Health Care Professionals, 1537
Levine JG: see Szarfman A, et al, 748
Levy EN: see Akins RL, et al, 694
Levy RD: see Ting LSL, et al, 1232
Lewis D: see Oh JJ, et al, 569
Lewis RE: Decision Making in Antifungal Monotherapy versus Combination Therapy, 61S
Lewis TV, Badillo R, Schaeffer S, Hagemann TM, McGoodwin L: Salicylate Toxicity Associated with Administration of Percy Medicine in an Infant, 403
Li J: see Morris AB, et al, 483
Lichtenstein KA: see Kiser JJ, et al, 511
Lieberman JM: see Le J, et al, 1758
Liewehr DJ: see Figg WD, et al, 759
Lipka O: see Cawley MJ, et al, 563
Liu B-M: see Wang Y-CL, et al, 143
Liu-DeRyke X, Rhoney DH: Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage: An Overview of Pharmacologic Management, 182
Lodise TP, Lomaestro BM, Drusano GL: Application of Antimicrobial Pharmacodynamic Concepts into Clinical Practice: Focus on β-Lactam Antibiotics: Insights from the Society of Infectious Diseases Pharmacists, 1320
Lodolce AE: see Aston JL, et al, 1314
Lomaestro BM: see Lodise TP, et al, 1320
Lomaestro BW: see Miller CD, et al, 877
Long C: see Raebel MA, et al, 619
Loomis IB: see Johnson JL, et al, 414
Lopes G: see Garcia S, et al, 440
Lowe DO, Knowles SR, Weber EA, Railton CJ, Shear NH: Povidone-Iodine–Induced Burn: Case Report and Review of the Literature, 1641
Lowe JF, Frazee LA: Update on Prostate Cancer Chemoprevention, 353
Lu Y-H: see Wang Y-CL, et al, 143
Luckritz TC: see Wells CD, et al, 1802
Luo X: see Zineh I, et al, 333
Lyons EE: see Raebel MA, et al, 619

- M -

Mabuchi H: see Asano A, et al, 447
Machado LS: see Elewa HF, et al, 515
Maciejewski S, Mohiuddin SM, Packard KA, Mooss AN, Reyes AP, Aryana A, Hilleman DE: Randomized, Double-Blind, Crossover Comparison of Amlodipine and Valsartan in African-Americans with Hypertension Using 24-Hour Ambulatory Blood Pressure Monitoring, 889
MacKeigan L: see Dupuis LL, et al, 1221
Magid DJ: see Raebel MA, et al, 619
Malesker M: see Morrow LE, et al, 1529
Malone DC: see Ko Y, et al, 1694
Marcheix A: see Laroche M-L, et al, 1041
Maree AO: see Levine GN, et al, 1537
Margolick JB: see Sabundayo BP, et al, 674
Marion-Latard F: see Tavassoli N, et al, 154
Markham-Abedi C: see Villanueva N, et al, 1352
Marrone CM: see Rubeiz GJ, et al, 428
Martinez LD: see ACCP, et al, 1816
Massip P: see Tavassoli N, et al, 154
Mathews S, Cole J, Ryono RA: Anticoagulation-Related Outcomes in Patients Receiving Warfarin After Starting Levofloxacin or Gatifloxacin, 1446
Mazzolini TA: see Irons BK, et al, 168
McArthur JH: see Sabundayo BP, et al, 674
McCabe SE: see Teter CJ, et al, 1501
McCall KL, Craddock D, Edwards K: Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Blockers on the Rate of New-Onset Diabetes Mellitus: A Review and Pooled Analysis, 1297
McCann E: see Studdiford J, et al, 1658
McCloskey DJ: see Horne III MK, et al, 1262
McConnell KJ, Zadvorny EB, Hardy AM, Delate T, Rasmussen JR, Merenich JA: Coronary Artery Disease and Hypertension: Outcomes of a Pharmacist-Managed Blood Pressure Program, 1333
McCord AD: Clinical Impact of a Pharmacist-Managed Diabetes Mellitus Drug Therapy Management Service, 248
McCulloch CE: see Mendez MN, et al, 61
McDermott MT: see Golightly LK, et al, 1421
McDonnell AM, Lenz KL, Frei-Lahr DA, Hayslip J, Hall PD: Single-Dose Rasburicase 6 mg in the

Management of Tumor Lysis Syndrome in Adults, 806
McDonough KL: see Bullano MF, et al, 469
McDonough RP: see Garwood CL, et al, 881
McGoodwin L: see Lewis TV, et al, 403
McLaughlin TP: see Dasta JF, et al, 798
McNeely C: see Villanueva N, et al, 1352
McRogers R: Not All Intravenous Immunoglobulins Are the Same: Appropriate Selection in Patients with Compromised Renal Function, 296
Meis GM: see Hanje AJ, et al, 1018
Mendez MN, Gibbs L, Jacobs RA, McCulloch CE, Winston L, Guglielmo BJ: Impact of a Piperacillin-Tazobactam Shortage on Antimicrobial Prescribing and the Rate of Vancomycin-Resistant Enterococci and Clostridium difficile Infections, 61
Merenich JA: see McConnell KJ, et al, 1333
Merle L: see Laroche M-L, et al, 1041
Miano TA, Crouch MA: Evolving Role of Vasopressin in the Treatment of Cardiac Arrest, 828
Micek ST, Heuring TJ, Hollands JM, Shah RA, Kollef MH: Optimizing Antibiotic Treatment for Ventilator-Associated Pneumonia, 204
Michaud LB: see Kintzel PE, et al, 853
Mikdashi JA: see Patterson SL, et al, 1518
Miller C: see Raebel MA, et al, 619
Miller CD, Lomaestro BW, Park S, Perlin DS: Progressive Esophagitis Caused by Candida albicans with Reduced Susceptibility to Caspofungin, 877
Miller WA: Changing the Structure of Pharmaceutical Education to Require Doctor of Pharmacy and Postgraduate Residency Education and Training, 587
Min B: see Caron MD, et al, 1241
Moeller KE, Barnes BJ: Compliance of an Institution-Specific Alcohol Withdrawal Protocol with Evidence-Based Practice Guidelines, 445
Moffett BS, Cannon BC, Friedman RA, Kertesz NJ: Therapeutic Levels of Intravenous Procainamide in Neonates: A Retrospective Assessment, 1687
Moffett BS, Jefferies JL, Price JF, Clunie S, Denfield S, Dreyer WJ, Towbin JA: Administration of a Large Nesiritide Bolus Dose in a Pediatric Patient: Case Report and Review of Nesiritide Use in Pediatrics, 277
Moffett BS, Jefferies JL, Rossano J, Towbin JA: Nesiritide Therapy in a Term Neonate with Renal Disease, 281
Mohiuddin SM: see Maciejewski S, et al, 889
Montague D: see Dorsch MP, et al, 423
Montastruc JL: see Tavassoli N, et al, 154
Mooss AN: see Maciejewski S, et al, 889
Morris AB, Li J, Kroenke K, Bruner-England TE, Young JM, Murray MD: Factors Associated with Drug Adherence and Blood Pressure Control in Patients with Hypertension, 483
Morris M: see DiCenzo R, et al, 1255
Morrow LE, Wear RE, Schuller D, Malesker M: Acute Isoniazid Toxicity and the Need for Adequate Pyridoxine Supplies, 1529
Morse BC: see Hummel MC, et al, 1667
Morse GD: see Tomilo DL, et al, 341
Mort JR, Aparasu RR, Baer RK: Interaction Between Selective Serotonin Reuptake Inhibitors and Nonsteroidal Antiinflammatory Drugs: Review of the Literature, 1307
Mullins ME: see Barnes BJ, et al, 23
Munger MA: Management of Acute Decompensated Heart Failure: Treatment, Controversy, and Future Directions, 131S
Murase Y: see Asano A, et al, 447
Murphy JE: see ACCP, et al, 1816
Murphy JE: see ACCP, et al, 722
Murray MD: see Morris AB, et al, 483
Murray MD: see Stroupe KT, et al, 779
Myers T: The Value of Care Algorithms, 181S

- N -

Nappi JM: see ACCP, et al, 722
Nappi JM: see Dang CH, et al, 461
Natale JJ: see Beumer JH, et al, 903
Nenciu LM, Laberge P, Thirion DJG: Telithromycin-Induced Digoxin Toxicity and Electrocardiographic Changes, 872
Newsom EE: see Raebel MA, et al, 619
Ng JA, Goldberg N, Tafreshi MJ: Clopidogrel-Induced Hepatotoxicity and Fever, 1023
Nichols J: see Wittbrodt E, et al, 203S
Nogid A, Pham DQ: Adjunctive Therapy with Pramlintide in Patients with Type 1 or Type 2 Diabetes Mellitus, 1626
Nohara A: see Asano A, et al, 447
Norgard NB, Stark JE: Olanzapine-Associated Neuroleptic Malignant Syndrome, 1180
Norman H: see Cole JA, et al, 1157
Noskin GA: see Scheetz MH, et al, 539
Notebaert E: see Darveau M, et al, 1587

- O -

O'Donnell PJ: see Parrish II RH, et al, 1650
Obadia M: see Tavassoli N, et al, 154
Obering CD, Chen JJ, Swope DM: Update on Apomorphine for the Rapid Treatment of Hypomobility ("Off") Episodes in Parkinson's Disease, 840
Oderda GM: see Creekmore FM, et al, 1438
Ogundele AB: see Tomilo DL, et al, 341
Oh JJ, Akers WS, Lewis D, Ramaiah C, Flynn JD: Recombinant Factor VIIa for Refractory Bleeding After Cardiac Surgery Secondary to Anticoagulation with the Direct Thrombin Inhibitor Lepirudin, 569
Oh JM: see Lee JY, et al, 1069
Oinonen MJ: see Arnold LM, et al, 1078
Okamoto LJ: Outcomes and Humanistic Issues Related to Treatment of Acute Bronchospasm, 175S
Olin JL, Spooner LM: Amphotericin B–Associated Hyperbilirubinemia: Case Report and Review of the Literature, 1011
Olson KL: see ACCP, et al, 1027
Oppenheim L: see Studdiford J, et al, 1658

Orringer EP: see Ataga KI, et al, 1557
Osei K: see Jain R, et al, 1388
Osterhaus M: see John EJ, et al, 1511
Owens Jr RC: Clostridium difficile–Associated Disease: An Emerging Threat to Patient Safety: Insights from the Society of Infectious Diseases Pharmacists, 299
Oyen LJ: see Stollings JL, et al, 1453

- P, Q -

Packard KA: see Maciejewski S, et al, 889
Padiyara RS: see Wenzel RG, et al, 375
Page II RL: see ACCP, et al, 1816
Page II RL: see Hemstreet BA, et al, 551
Pande RU: see Qureshi AI, et al, 493
Papoushek C: see Langford BJ, et al, 260
Park S: see Miller CD, et al, 877
Parnes HL, Figg WD: Chemoprevention in Prostate Cancer, 1533
Parrish II RH, Pazdur DE, O'Donnell PJ: Effect of Carbamazepine Initiation and Discontinuation on Antithrombotic Control in a Patient Receiving Warfarin: Case Report and Review of the Literature, 1650
Partovi N: see Ting LSL, et al, 1232
Patanwala AE, Abarca J, Huckleberry Y, Erstad BL: Pharmacologic Management of Constipation in the Critically Ill Patient, 896
Patel BM: see Wells CD, et al, 1802
Patel I: see True AL, et al, 1679
Patterson C: see Dorsch MP, et al, 423
Patterson SL, LaMonte MP, Mikdashi JA, Haines ST, Hursting MJ: Anticoagulation Strategies for Treatment of Ischemic Stroke and Antiphospholipid Syndrome: Case Report and Review of the Literature, 1518
Patton ML: see Varghese SP, et al, 699
Pauly DF: see Beitelshees AL, et al, 1247
Pazdur DE: see Parrish II RH, et al, 1650
Pendleton RC: see Creekmore FM, et al, 1438
Penzak SR: see Robertson SM, et al, 1051
Peres E: see Said A, et al, 289
Perez AT: see Jain R, et al, 1388
Perkins AM: see Wolowich WR, et al, 1268
Perlin DS: see Miller CD, et al, 877
Peterman CM, Kolansky DM, Spinler SA: Prophylaxis Against Venous Thromboembolism in Acutely Ill Medical Patients: An Observational Study, 1086
Pettignano R: see Tilelli JA, et al, 147
Pham DQ: see Nogid A, et al, 1626
Piacenti FJ: An Update and Review of Antiretroviral Therapy, 1111
Piccininni LC: see Takiya L, et al, 115
Pleasants RA: Review of Guidelines and the Literature in the Treatment of Acute Bronchospasm in Chronic Obstructive Pulmonary Disease, 156S
Polimeni G: see Galatti L, et al, 1190
Pope SD, Roecker AM: Dalbavancin: A Novel Lipoglycopeptide Antibacterial, 908
Postelnick MJ: see Scheetz MH, et al, 539
Predko L: see DiCenzo R, et al, 1255
Price JF: see Moffett BS, et al, 277
Prichard JG: see Kang-Birken SL, et al, 1646
Prince HM: see Kenealy MK, et al, 1205
Qazi KJ: see Qureshi AI, et al, 493
Quinn JA, Snyder SL, Berghoff JL, Colombo CS, Jacobi J: A Practical Approach to Hyperglycemia Management in the Intensive Care Unit: Evaluation of an Intensive Insulin Infusion Protocol, 1410
Qureshi AI, Kirmani JF, Safdar A, Ahmed S, Sayed MA, Pande RU, Ferguson R, Hershey LA, Qazi KJ: High Prevalence of Previous Antiplatelet Drug Use in Patients with New or Recurrent Ischemic Stroke: Buffalo Metropolitan Area and Erie County Stroke Study, 493

- R -

Rady MY: see Wells CD, et al, 1802
Raebel MA, Chester EA, Newsom EE, Lyons EE, Kelleher JA, Long C, Miller C, Magid DJ: Randomized Trial to Improve Laboratory Safety Monitoring of Ongoing Drug Therapy in Ambulatory Patients, 619
Raehl CL: see Bond CA, et al, 1369
Raehl CL: see Bond CA, et al, 601
Raehl CL: see Bond CA, et al, 735
Ragucci KR: see Shrader SP, et al, 1403
Railton CJ: see Lowe DO, et al, 1641
Raissy HH: see Wittbrodt E, et al, 203S
Ramaiah C: see Oh JJ, et al, 569
Ramin SM: see Badell ML, et al, 1273
Rancourt JA: see Gillespie EL, et al, 499
Raptis A: see Beumer JH, et al, 903
Rasmussen JR: see McConnell KJ, et al, 1333
Ray MD: Clinical Maturity in Pharmacy, 594
Regalia RC: see Albertson TE, et al, 1091
Reichert MG: see ACCP, et al, 1816
Reichman R: see DiCenzo R, et al, 1255
Reyes AP: see Maciejewski S, et al, 889
Rhoney DH: see Liu-DeRyke X, et al, 182
Rice III WY: see Hammons KB, et al, 1165
Riggs KW: see Ting LSL, et al, 1232
Roberts M: see Samoy LJ, et al, 1578
Robertson SM, Formentini E, Alfaro RM, Falloon J, Penzak SR: Lack of In Vivo Correlation Between Indinavir and Saquinavir Exposure and Cytochrome P450 3A Phenotype as Assessed with Oral Midazolam as a Phenotype Probe, 1051
Rodgers JE: see Dorsch MP, et al, 1465
Rodgers JE: see Dorsch MP, et al, 423
Rodgers PT, Fuke DC: New and Emerging Strategies for Reducing Cardiometabolic Risk Factors, 13S
Rodgers PT: see Haines ST, et al, 32S
Roecker AM: see Pope SD, et al, 908
Romanelli F, Smith KM: Clinical Effects and Management of Methamphetamine Abuse, 1148
Romani M: see Galatti L, et al, 1190
Rose WE, Rybak MJ: Tigecycline: First of a New Class of Antimicrobial Agents, 1099
Rosenfield K: see Levine GN, et al, 1537

Rossano J: see Moffett BS, et al, 281
Rozenfeld Y, Hunt JS: Effect of Patient Withdrawal on a Study Evaluating Pharmacist Management of Hypertension, 1565
Rubeiz GJ, Marrone CM, Leclerc JR: Treatment of Heparin-Induced Thrombocytopenia with Drotrecogin Alfa (activated), 428
Russmann S: see Jick H, et al, 1379
Rybak MJ: see Rose WE, et al, 1099
Ryono RA: see Mathews S, et al, 1446

- S -

Saad AH, DePestel DD, Carver PL: Factors Influencing the Magnitude and Clinical Significance of Drug Interactions Between Azole Antifungals and Select Immunosuppressants, 1730
Sabundayo BP, McArthur JH, Langan SJ, Gallant JE, Margolick JB: High Frequency of Highly Active Antiretroviral Therapy Modifications in Patients with Acute or Early Human Immunodeficiency Virus Infection, 674
Safdar A: see Qureshi AI, et al, 493
Said A, Garnick JJ, Dieterle N, Peres E, Abidi MH, Ibrahim RB: Sirolimus-Itraconazole Interaction in a Hematopoietic Stem Cell Transplant Recipient, 289
Salvo F: see Galatti L, et al, 1190
Samoy LJ, Zed PJ, Wilbur K, Balen RM, Abu-Laban RB, Roberts M: Drug-Related Hospitalizations in a Tertiary Care Internal Medicine Service of a Canadian Hospital: A Prospective Study, 1578
Sander S, White CM, Coleman CI: Comparative Safety and Efficacy of Urokinase and Recombinant Tissue Plasminogen Activator for Peripheral Arterial Occlusion: A Meta-Analysis, 51
Sanoski CA: see Dager WE, et al, 1703
Saseen JJ: see ACCP, et al, 1816
Saseen JJ: see ACCP, et al, 722
Saunders EF: see Dupuis LL, et al, 15
Sayed MA: see Qureshi AI, et al, 493
Schaeffer S: see Lewis TV, et al, 403
Scheetz MH, Wunderink RG, Postelnick MJ, Noskin GA: Potential Impact of Vancomycin Pulmonary Distribution on Treatment Outcomes in Patients with Methicillin-Resistant Staphylococcus aureus Pneumonia, 539
Scheife RT, Cavanaugh SE: Higher, Faster, Farther, 151
Schofiel[illegible] RS: see Welder GJ, et al, 1794
Schofield RS: see Zineh I, et al, 1572
Schofield RS: see Zineh I, et al, 333
Schonder KS: see Corman SL, et al, 1433
Schuller D: see Morrow LE, et al, 1529
Schwartz AH: see Bruce SP, et al, 1193
Schwarz K: see Wenzel RG, et al, 375
Seamon MJ: see Cubeddu LX, et al, 1288
Segreti JA, Crank CW, Finney MS: Daptomycin for the Treatment of Gram-Positive Bacteremia and Infective Endocarditis: A Retrospective Case Series of 31 Patients, 347
Sessa A: see Galatti L, et al, 1190
Sesti A-M: see Dasta JF, et al, 798
Seybert AL, Coons JC, Zerumsky K: Treatment of Heparin-Induced Thrombocytopenia: Is There a Role for Bivalirudin?, 229
Shah AD: see Clark BM, et al, 705
Shah RA: see Micek ST, et al, 204
Shah SR: see Villela LR, et al, 641
Shamp JL: see Hanje AJ, et al, 1018
Shamsi SA: see Jann MW, et al, 627
Shapiro NL, Durr EA, Krueger CD: Prolonged Anticoagulation After Discontinuation of Argatroban and Warfarin Therapy in an Obese Patient with Heparin-Induced Thrombocytopenia, 1806
Shapiro NL: see Aston JL, et al, 1314
Shear NH: see Lowe DO, et al, 1641
Shimizu M: see Asano A, et al, 447
Shin WG: see Lee JY, et al, 1069
Shrader SP, Ragucci KR: Life After the Women's Health Initiative: Evaluation of Postmenopausal Symptoms and Use of Alternative Therapies After Discontinuation of Hormone Therapy, 1403
Sims KA, Woodland AM: Entecavir: A New Nucleoside Analog for the Treatment of Chronic Hepatitis B Infection, 1745
Sleeper RB: see Irons BK, et al, 168
Smith JA: see ACCP, et al, 1027
Smith JA: see Badell ML, et al, 1273
Smith JR: see Barnes BJ, et al, 23
Smith KM: see Romanelli F, et al, 1148
Smith KM: see Tilelli JA, et al, 147
Smith PF: see Tomilo DL, et al, 341
Snyder SL: see Quinn JA, et al, 1410
Sobel JD: Design of Clinical Trials of Empiric Antifungal Therapy in Patients with Persistent Febrile Neutropenia: Considerations and Critiques, 47S
Sommet A: see Tavassoli N, et al, 154
Son IJ: see Lee JY, et al, 1069
Sowinski KM, Wright JM: Preparation for the Pharmacotherapy Specialty Certification Examination: Are Question Cues Enough?, 1675
Sowinski KM: see ACCP, et al, 1027
Spina E: see Galatti L, et al, 1190
Spinler SA: Challenges Associated with Metabolic Syndrome, 209S
Spinler SA: Introduction, 207S
Spinler SA: see ACCP, et al, 722
Spinler SA: see Holtzman CW, et al, 1601
Spinler SA: see Levine GN, et al, 1537
Spinler SA: see Peterman CM, et al, 1086
Spinler SA: ST-Segment–Elevation Myocardial Infarction: Guidelines and the Challenge of Real-World Patient Care, 115S
Spooner LM: see Olin JL, et al, 1011
Spratlin V: see Jann MW, et al, 627
Staat DD, Klepser ME: International Adoption: Issues in Infectious Diseases, 1207
Stacy ZA, Dobesh PP, Trujillo TC: Cardiovascular Risks of Cyclooxygenase Inhibition, 919

Stanford BL: see Villela LR, et al, 641
Stark JE: see Norgard NB, et al, 1180
Steffensmeier JJG, Ernst ME, Kelly M, Hartz AJ: Do Randomized Controlled Trials Always Trump Case Reports? A Second Look at Propranolol and Depression, 162
Steinberg SM: see Figg WD, et al, 759
Stevens CE: see Garner SS, et al, 1396
Stimmel GL, Gutierrez MA: Counseling Patients About Sexual Issues, 1608
Stocker JW: see Ataga KI, et al, 1557
Stollings JL, Oyen LJ: Oxygen Therapeutics: Oxygen Delivery Without Blood, 1453
Stolpman NM: see Golightly LK, et al, 1421
Storms LE, Chicella MF, Dice JE: Sevelamer Therapy for Pediatric End-Stage Renal Disease, 410
Stout R: see True AL, et al, 1679
Strachan PM, Benoff BA: Mental Status Change, Myoclonus, Electrocardiographic Changes, and Acute Respiratory Distress Syndrome Induced by Quetiapine Overdose, 578
Straley CM, Cecil EJ, Herriman MP: Gatifloxacin Interference with Opiate Urine Drug Screen, 435
Stringer KA: see ACCP, et al, 1816
Stroup JS, Haraway GD, Beal JM: Aprotinin in the Management of Coagulopathy Associated with Amniotic Fluid Embolus, 689
Stroupe KT, Teal EY, Tu W, Weiner M, Murray MD: Association of Refill Adherence and Health Care Use Among Adults with Hypertension in an Urban Health Care System, 779
Studdiford J, Oppenheim L, McCann E, Altshuler M: Erythema Multiforme After Meningitis Vaccine: Patient Safety Concerns with Repeat Immunization, 1658
Styles L: see Ataga KI, et al, 1557
Suh KS: see Lee JY, et al, 1069
Sullivan AL: see Garwood CL, et al, 881
Summers KM, Holdford DA, Crouch MA: Cost-Effectiveness Analysis of Antithrombotic Therapy in Nonurgent Percutaneous Coronary Intervention, 609
Supernaw RB: see Wang Y-CL, et al, 143
Swerdlow P: see Ataga KI, et al, 1557
Swope DM: see Obering CD, et al, 840
Sysko SK: see Haines ST, et al, 32S
Sysko SK: see Lender D, et al, 3S
Szarfman A, Tonning JM, Levine JG, Doraiswamy PM: Atypical Antipsychotics and Pituitary Tumors: A Pharmacovigilance Study, 748
Szumita PM: see Anger KE, et al, 214

- T -

Taddio A: see Dupuis LL, et al, 1221
Tafreshi MJ, Zagnoni LG, Gentry EJ: Combination of Clopidogrel and Statins: A Hypothetical Interaction or Therapeutic Dilemma?, 388
Tafreshi MJ: see Ng JA, et al, 1023
Takiya L, Piccininni LC, Kamath V: Safety and Efficacy of Eletriptan in the Treatment of Acute Migraine, 115
Talbert RL: Introduction, 113S
Talbert RL: The Challenge of Blood Pressure Management in Neurologic Emergencies, 123S
Talbert RL: see Ito MK, et al, 85S
Tavassoli N, Bagheri H, Sommet A, Delpierre C, Marion-Latard F, Massip P, Aquilina C, Bonnet E, Obadia M, Labau E, Montastruc JL, Bernard J: Effects of Discontinuing Stavudine or Protease Inhibitor Therapy on Human Immunodeficiency Virus–Related Fat Redistribution Evaluated by Dual-Energy X-Ray Absorptiometry, 154
Taylor CT: see ACCP, et al, 1816
Taylor DM, Walsham N, Taylor SE, Wong LF: Potential Interactions Between Prescription Drugs and Complementary and Alternative Medicines Among Patients in the Emergency Department, 634
Taylor JR: Probable Interaction Between Tolterodine and Warfarin, 719
Taylor SE: see Taylor DM, et al, 634
Taylor T: see Dupuis LL, et al, 15
Teal EY: see Stroupe KT, et al, 779
Terrell AR: see Barnes BJ, et al, 23
Terriff CM: see Brouillard JE, et al, 3
Teter CJ, McCabe SE, LaGrange K, Cranford JA, Boyd CJ: Illicit Use of Specific Prescription Stimulants Among College Students: Prevalence, Motives, and Routes of Administration, 1501
Thai XC, Bruno-Murtha LA: Bell's Palsy Associated with Linezolid Therapy: Case Report and Review of Neuropathic Adverse Events, 1183
Tharratt RS: see Albertson TE, et al, 1091
Thirion DJG: see Nenciu LM, et al, 872
Thomas FB: see Hanje AJ, et al, 1018
Thurman PW: see Figg WD, et al, 759
Tilelli JA, Smith KM, Pettignano R: Life-Threatening Bradyarrhythmia After Massive Azithromycin Overdose, 147
Ting LSL, Partovi N, Levy RD, Riggs KW, Ensom MHH: Limited Sampling Strategy for Predicting Area Under the Concentration-Time Curve of Mycophenolic Acid in Adult Lung Transplant Recipients, 1232
Tisdale JE: see Dager WE, et al, 1703
Tjon J: see Lam C, et al, 1811
Tofan A: see Brouillard JE, et al, 3
Tomilo DL, Smith PF, Ogundele AB, Difrancesco R, Berenson CS, Eberhardt E, Bednarczyk E, Morse GD: Inhibition of Atazanavir Oral Absorption by Lansoprazole Gastric Acid Suppression in Healthy Volunteers, 341
Tonning JM: see Szarfman A, et al, 748
Touchette D: see ACCP, et al, 1027
Towbin JA: see Moffett BS, et al, 277
Towbin JA: see Moffett BS, et al, 281
Townsend KA, Eiland LS: Combating Influenza with Antiviral Therapy in the Pediatric Population, 95
Townsend RR: see Hennessy S, et al, 1342
Triller DM: see Williams EM, et al, 713
Triplitt C, Wright A, Chiquette E: Incretin Mimetics

and Dipeptidyl Peptidase-IV Inhibitors: Potential New Therapies for Type 2 Diabetes Mellitus, 360
True AL, Chiu Y-Y, DeMasi RA, Stout R, Patel I: Pharmacokinetic Bioequivalence of Enfuvirtide Using a Needle-Free Device versus Standard Needle Administration, 1679
Trujillo TC: see Stacy ZA, et al, 919
Tsimikas S: see Ito MK, et al, 85S
Tu W: see Stroupe KT, et al, 779
Turrentine MW: see Knoderer CA, et al, 709

- U, V -

van der Elst ME, Bouvy ML, de Blaey CJ, de Boer A: Improving Pharmacotherapy After Myocardial Infarction by Group Academic Detailing Using Feedback Data on a Patient Level, 254
Van Schepen KA: see Garwood CL, et al, 881
Varghese SP, Haith Jr LR, Patton ML, Guilday RE, Ackerman BH: Lamotrigine-Induced Toxic Epidermal Necrolysis in Three Patients Treated for Bipolar Disorder, 699
Vavra T: see John EJ, et al, 1511
Vichinsky EP: see Ataga KI, et al, 1557
Villanueva N, Markham-Abedi C, McNeely C, Diaz FJ, de Leon J: Probable Association Between Ziprasidone and Worsening Hypertension, 1352
Villela LR, Stanford BL, Shah SR: Pemetrexed, a Novel Antifolate Therapeutic Alternative for Cancer Chemotherapy, 641
von Hippel E: see DeMonaco HJ, et al, 323
Vondracek SF, Hemstreet BA: Is There an Optimal Corticosteroid Regimen for the Management of an Acute Exacerbation of Chronic Obstructive Pulmonary Disease?, 522

- W -

Walker AM: see Cole JA, et al, 1157
Walker JB: see Divittorio G, et al, 104
Walsham N: see Taylor DM, et al, 634
Wang Y-CL, Liu B-M, Supernaw RB, Lu Y-H, Lee P-Y: Management of Star Fruit–Induced Neurotoxicity and Seizures in a Patient with Chronic Renal Failure, 143
Ward CT, Chavalitanonda N: Atypical Warfarin-Induced Skin Necrosis, 1175
Wasserstein AG: see Hennessy S, et al, 1342
Weant KA, Flynn JF, Akers WS: Management of Antiplatelet Therapy for Minimization of Bleeding Risk Before Cardiac Surgery, 1616
Wear RE: see Morrow LE, et al, 1529
Weatherby LB: see Cole JA, et al, 1157
Weber EA: see Lowe DO, et al, 1641
Weiner M: see Stroupe KT, et al, 779
Welder GJ, Wessel TR, Arant CB, Schofield RS, Zineh I: Complementary and Alternative Medicine Use Among Individuals Participating in Research: Implications for Research and Practice, 1794
Welder GJ: see Zineh I, et al, 1572
Welder GJ: see Zineh I, et al, 333
Welker W: see Divittorio G, et al, 104
Wells CD, Luckritz TC, Rady MY, Zornik JM, Leighton JA, Patel BM: Bezoar Formation Requiring Endoscopic Removal After Intentional Overdose of Extended-Release Nifedipine, 1802
Welty TE: see ACCP, et al, 722
Wenzel RG, Schwarz K, Padiyara RS: Topiramate for Migraine Prevention, 375
Wermeling DP, Berger JR: Ziconotide Infusion for Severe Chronic Pain: Case Series of Patients with Neuropathic Pain, 395
Wertz DA: see Bullano MF, et al, 469
Wesley R: see Horne III MK, et al, 1262
Wessel TR: see Welder GJ, et al, 1794
Wessel TR: see Zineh I, et al, 1572
Wessel TR: see Zineh I, et al, 333
White CM: see Caron MD, et al, 1241
White CM: see Gillespie EL, et al, 499
White CM: see Sander S, et al, 51
White RH: see Albertson TE, et al, 1091
Whitley HP, Fermo JD, Chumney ECG: 5-Year Evaluation of Electronic Medical Record Flag Alerts for Patients Warranting Secondary Prevention of Coronary Heart Disease, 682
Wiest DB: see Garner SS, et al, 1396
Wiggins BS: see Dager WE, et al, 1703
Wiggins BS: see Holtzman CW, et al, 1601
Wiggins BS: see Levine GN, et al, 1537
Wilbur K: see Samoy LJ, et al, 1578
Willey VJ: see Bullano MF, et al, 469
Williams D: Acute Bronchospasm from the Patient's Perspective: Role of Patient Education, 193S
Williams EM, Triller DM: Recurrent Acute Nitrofurantoin-Induced Pulmonary Toxicity, 713
Williamson D: see Albertson TE, et al, 1091
Williamson DR: see Darveau M, et al, 1587
Winston L: see Mendez MN, et al, 61
Winterstein AG: see Gerhard T, et al, 34
Wittbrodt E, Koval P, Raissy HH, Nichols J: Treatment Algorithms from the Pharmacist Perspective, 203S
Wolowich WR, Perkins AM, Cienki JJ: Analysis of the Psychoactive Terpenoid Salvinorin A Content in Five Salvia divinorum Herbal Products, 1268
Wong LF: see Taylor DM, et al, 634
Woodland AM: see Sims KA, et al, 1745
Wright A: see Triplitt C, et al, 360
Wright JM: see Sowinski KM, et al, 1675
Wunderink RG: see Scheetz MH, et al, 539

-X, Y-

Yang GW: see Bullano MF, et al, 469
Yang W: see Hennessy S, et al, 1342
Yarandi HN: see Beitelshees AL, et al, 1247
Yi NJ: see Lee JY, et al, 1069
Yin OQP, Lau S-K, Chow MSS: Population Pharmacokinetics of Cyclosporine in Chinese Cardiac Transplant Recipients, 790
Young JM: see Morris AB, et al, 483

-Z-

Zadvorny EB: see McConnell KJ, et al, 1333

Zagnoni LG: see Tafreshi MJ, et al, 388
Zed PJ: see Samoy LJ, et al, 1578
Zerumsky K: see Seybert AL, et al, 229
Zhang B: see Etminan M, et al, 479
Zhang J: see Jain R, et al, 1388
Zheng J: see Jann MW, et al, 627
Zineh I, Luo X, Welder GJ, DeBella AE, Wessel TR, Arant CB, Schofield RS, Chegini N: Modulatory Effects of Atorvastatin on Endothelial Cell–Derived Chemokines, Cytokines, and Angiogenic Factors, 333
Zineh I, Welder GJ, DeBella AE, Arant CB, Wessel TR, Schofield RS: Atorvastatin Effect on Circulating and Leukocyte-Produced CD40 Ligand Concentrations in People with Normal Cholesterol Levels: A Pilot Study, 1572
Zineh I: see Beitelshees AL, et al, 1247
Zineh I: see Gerhard T, et al, 34
Zineh I: see Welder GJ, et al, 1794
Zornik JM: see Wells CD, et al, 1802

Index to Volume 26

Subject Index

- A -

Abciximab-associated thrombocytopenia after previous tirofiban-related thrombocytopenia, 423

ACCP 2006 Annual Meeting: abstracts and index of authors, 1535

ACCP 2006 Spring Practice and Research Forum abstracts and index of authors, 734

ACCP cardiology practice research network: percutaneous coronary interventions, newer pharmacotherapy in patients undergoing, a guide for pharmacists and other health care professionals, 1537

ACCP position statement: American College of Clinical Pharmacy's vision of the future: post-graduate pharmacy residency training as a prerequisite for direct patient care practice, 722

ACCP white paper: critical pathways: the role of pharmacy today and tomorrow, 1358

ACCP white paper: future clinical pharmacy practitioners should be board-certified specialists, 1816

ACCP white paper: the state of science and research in clinical pharmacy, 1027

ACCP white paper: utilization of the center for the advancement of pharmaceutical education educational outcomes, revised version 2004: report of the 2005 American College of Clinical Pharmacy Educational Affairs Committee, 1193

ACLS, pharmacotherapy considerations in, 1703

Acquired immunodeficiency syndrome, Mycobacterium szulgai in a patient with advanced, an unusual pathogen with unusual multidrug resistance, 1646

Adherence and blood pressure control in patients with hypertension, factors associated with drug 483

Advanced cardiac life support, pharmacotherapy considerations in, 1703

Adverse drug reactions in United States hospitals, 601

Adverse drug reactions, clinical pharmacy services, pharmacy staffing, and, in United States hospitals, 735

Albuterol delivery, effect of heliox on, by metered-dose inhaler in pediatric in vitro models of mechanical ventilation, 1396

Alcohol withdrawal protocol, compliance of an institution-specific, with evidence-based practice guidelines, 445

Algorithms, the value of care, 181S

Algorithms, treatment, from the pharmacist perspective, 203S

Alternative and complementary medicine use among individuals participating in research: implications for research and practice, 1794

Alternative medicines, potential interactions between prescription drugs and complementary and, among patients in the emergency department, 634

Alternative viewpoints: not all intravenous immunoglobulins are the same: appropriate selection in patients with compromised renal function, 296

Ambulatory blood pressure monitoring, randomized, double-blind, crossover comparison of amlodipine and valsartan in African-Americans with hypertension using 24-hour, 889

Ambulatory patients, randomized trial to improve laboratory safety monitoring of ongoing drug therapy in, 619

Amiodarone, cost-effectiveness of, for prophylaxis of atrial fibrillation after cardiothoracic surgery, 499

Amlodipine and valsartan, randomized, double-blind, crossover comparison of, in African-Americans with hypertension using 24-hour ambulatory blood pressure monitoring, 889

Amniotic fluid embolus, aprotinin in the management of coagulopathy associated with, 689

Amphotericin B–associated hyperbilirubinemia: case report and review of the literature, 1011

Anaphylaxis, recurrent, associated with gonadotropin-releasing hormone analogs: case report and review of the literature, 1811

Angina, ranolazine, a novel agent for chronic stable, 135

Angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors, do they decrease the risk of hospitalization secondary to community-acquired pneumonia? A nested case-control study, 479

Angiotensin II type 1 receptor blockers, effect of angiotensin-converting enzyme inhibitors and, on the rate of new-onset diabetes mellitus: a review and pooled analysis, 1297

Angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers, effect of, on the rate of new-onset diabetes mellitus: a review and pooled analysis, 1297

Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, do they decrease the risk of hospitalization secondary to community-acquired pneumonia? A nested case-control study, 479

Antibiotic selection and resistance issues with fluoroquinolones and doxycycline against bioterrorism agents, 3

Anticoagulation strategies for treatment of ischemic stroke and antiphospholipid syndrome: case report and review of the literature, 1518

Anticoagulation, prolonged, after discontinuation of argatroban and warfarin therapy in an obese patient

with heparin-induced thrombocytopenia, 1806
Anticoagulation-related outcomes in patients receiving warfarin after starting levofloxacin or gatifloxacin, 1446
Antiepileptic drug therapy, clinical and economic outcomes of pharmacist-managed, 1369
Antifolate therapeutic alternative, pemetrexed, a novel, for cancer chemotherapy, 641
Antifungal monotherapy versus combination therapy, decision making in, 61S
Antifungal therapy, design of clinical trials of empiric, in patients with persistent febrile neutropenia: considerations and critiques, 47S
Antimuscarinic agents, pharmacoeconomic evaluation of, for the treatment of overactive bladder, 1694
Antineoplastic agents, development and validation of the pediatric nausea assessment tool for use in children receiving, 1221
Antiphospholipid syndrome, anticoagulation strategies for treatment of ischemic stroke and, case report and review of the literature, 1518
Antiplatelet drug resistance: almost ready for prime time (alternative viewpoints), 1201
Antiplatelet drug use, high prevalence of previous, in patients with new or recurrent ischemic stroke: Buffalo metropolitan area and Erie county stroke study, 493
Antiplatelet therapy, management of, for minimization of bleeding risk before cardiac surgery, 1616
Antipsychotics, atypical, and pituitary tumors: a pharmacovigilance study, 748
Antipsychotics, long-term use of atypical, in bipolar disorder, 1134
Antiretroviral therapy modifications, high frequency of highly active, in patients with acute or early human immunodeficiency virus infection, 674
Antiretroviral therapy, an update and review of, 1111
Antithrombotic therapy in nonurgent percutaneous coronary intervention, cost-effectiveness analysis of, 609
Antithymocyte globulin, rabbit, induction therapy in adult renal transplantation, 1771
Antiviral therapy, combating influenza with, in the pediatric population, 95
Apomorphine, update on, for the rapid treatment of hypomobility ("off") episodes in Parkinson's disease, 840
Aprotinin in the management of coagulopathy associated with amniotic fluid embolus, 689
Argatroban and warfarin therapy, prolonged anticoagulation after discontinuation of, in an obese patient with heparin-induced thrombocytopenia, 1806
Asthma, review of guidelines and the literature in the treatment of acute bronchospasm in, 148S
Atazanavir and fosamprenavir, effects of esomeprazole on the pharmacokinetics of, in a patient with human immunodeficiency virus infection, 511
Atazanavir oral absorption, inhibition of, by lansoprazole gastric acid suppression in healthy volunteers, 341
Atorvastatin effect on circulating and leukocyte-produced CD40 ligand concentrations in people with normal cholesterol levels: a pilot study, 1572
Atorvastatin therapy, golf-inhibiting gynecomastia associated with, 1165
Atorvastatin, modulatory effects of, on endothelial cell–derived chemokines, cytokines, and angiogenic factors, 333
Atrial fibrillation, cost-effectiveness of amiodarone for prophylaxis of, after cardiothoracic surgery, 499
Atypical antipsychotics and pituitary tumors: a pharmacovigilance study, 748
Atypical antipsychotics, long-term use of, in bipolar disorder, 1134
Avian influenza A (H5N1), pandemics, and a strategy for pharmacists, 312
Azithromycin overdose, life-threatening bradyarrhythmia after massive, 147
Azole antifungals and select immunosuppressants, factors influencing the magnitude and clinical significance of drug interactions between, 1730

- B -

Bell's palsy associated with linezolid therapy: case report and review of neuropathic adverse events, 1183
Beta$_2$-agonists, risk versus benefit considerations for the, 164S
Beta-blocker effects, discordant, on clinic, ambulatory, resting, and exercise hemodynamics in patients with hypertension, 1255
Beta-blockers, carvedilol versus cardioselective, for the treatment of hypertension in patients with type 2 diabetes mellitus, 1491
Beta-lactam antibiotics, application of antimicrobial pharmacodynamic concepts into clinical practice: focus on, Society of Infectious Diseases Pharmacists, 1320
Bezoar formation requiring endoscopic removal after intentional overdose of extended-release nifedipine, 1802
Bioterrorism agents, antibiotic selection and resistance issues with fluoroquinolones and doxycycline against, 3
Bipolar disorder, long-term use of atypical antipsychotics in, 1134
Bisphosphonate, ibandronate, an experimental intravenous, for osteoporosis, bone metastases, and hypercalcemia of malignancy, 655
Bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction, evaluation of, 452
Bivalirudin, treatment of heparin-induced thrombocytopenia: is there a role for, 229
Blood pressure management, the challenge of, in neurologic emergencies, 123S
Board-certified specialists, American College of Clinical Pharmacy white paper: future clinical pharmacy practitioners should be, 1816

Bone metastases, and hypercalcemia of malignancy, ibandronate, an experimental intravenous bisphosphonate for osteoporosis, 655
Bone mineral density and fracture risk reduction during pharmacologic treatment of osteoporosis, examining the relationship between, 104
Bradyarrhythmia, life-threatening, after massive azithromycin overdose, 147
Breakpoints, susceptibility, predicting the future, Monte Carlo simulation in the evaluation of, 129
Bronchospasm, acute, from the patient's perspective: role of patient education, 193S
Bronchospasm, outcomes and humanistic issues related to treatment of acute, 175S
Bronchospasm, review of guidelines and the literature in the treatment of acute, in asthma, 148S
Bronchospasm, review of guidelines and the literature in the treatment of acute, in chronic obstructive pulmonary disease, 156S

- C -

Candida albicans, progressive esophagitis caused by, with reduced susceptibility to caspofungin, 877
Candida resistance and its clinical relevance, 68S
Carbamazepine, effect of, initiation and discontinuation on antithrombotic control in a patient receiving warfarin: case report and review of the literature, 1650
Cardiac arrest, evolving role of vasopressin in the treatment of, 828
Cardiac surgery, management of antiplatelet therapy for minimization of bleeding risk before, 1616
Cardiometabolic risk factors, evaluating and treating: a case discussion, 32S
Cardiometabolic risk factors, new and emerging strategies for reducing, 13S
Cardiometabolic risk, addressing, 1S
Cardiometabolic risk, metabolic syndrome and, scope of the problem and current standard of care, 3S
Cardiovascular risk in patients with type 2 diabetes mellitus, implications of rosiglitazone and pioglitazone on, 168
Cardiovascular risk, implications of thiazolidinedione use and, is it all about the sugar (alternative viewpoint), 1049
Cardiovascular risks of cyclooxygenase inhibition, 919
Carvedilol versus cardioselective beta-blockers for the treatment of hypertension in patients with type 2 diabetes mellitus, 1491
Caspofungin, progressive esophagitis caused by Candida albicans with reduced susceptibility to, 877
Cefepime neurotoxicity: case report, pharmacokinetic considerations, and literature review, 1169
Cefotaxime-ciprofloxacin combination therapy for nontyphoid Salmonella bacteremia and paravertebral abscess after failure of monotherapy, 1671
Central venous access devices, use of heparin versus lepirudin flushes to prevent withdrawal occlusion of, 1262
Cerebral vasospasm after aneurysmal subarachnoid hemorrhage: an overview of pharmacologic management, 182
Chemotherapy, pemetrexed, a novel antifolate therapeutic alternative for cancer, 641
Chronic obstructive pulmonary disease, is there an optimal corticosteroid regimen for the management of an acute exacerbation of, 522
Chronic obstructive pulmonary disease, review of guidelines and the literature in the treatment of acute bronchospasm in, 156S
Ciprofloxacin-cefotaxime combination therapy for nontyphoid Salmonella bacteremia and paravertebral abscess after failure of monotherapy, 1671
Citation rates of published articles, scientific collaboration results in higher, 759
Clinical pharmacy services, pharmacy staffing, and adverse drug reactions in United States hospitals, 735
Clinical pharmacy, ACCP white paper: the state of science and research in, 1027
Clinicians, the major role of, in the discovery of off-label drug therapies, 323
Clopidogrel and statins, combination of: a hypothetical interaction or therapeutic dilemma, 388
Clopidogrel-induced hepatotoxicity and fever, 1023
Clostridium difficile infections, impact of a piperacillin-tazobactam shortage on antimicrobial prescribing, and the rate of vancomycin-resistant enterococci and, 61
Clostridium difficile–associated disease: an emerging threat to patient safety: insights from the Society of Infectious Diseases Pharmacists, 299
Coagulopathy associated with amniotic fluid embolus, aprotinin in the management of, 689
Collaboration, scientific, results in higher citation rates of published articles, 759
Community-acquired pneumonia: a nested case-control study, do angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers decrease the risk of hospitalization secondary to, 479
Complementary and alternative medicine use among individuals participating in research: implications for research and practice, 1794
Complementary and alternative medicines, potential interactions between prescription drugs and, among patients in the emergency department, 634
Constipation, pharmacologic management of, in the critically ill patient, 896
Coronary intervention, cost-effectiveness analysis of antithrombotic therapy in nonurgent percutaneous, 609
Corticosteroid regimen, is there an optimal, for the management of an acute exacerbation of chronic obstructive pulmonary disease, 522
Cranberry juice, interaction between warfarin and, 1314
Critical pathways: the role of pharmacy today and tomorrow, ACCP white paper, 1358
Cyclooxygenase inhibition, cardiovascular risks of, 919

Cyclosporine, disposition of two oral formulations of, in pediatric patients receiving hematopoietic stem cell transplants, 15
Cyclosporine, population pharmacokinetics of, in Chinese cardiac transplant recipients, 790

- D -

Dalbavancin: a novel lipoglycopeptide antibacterial, 908
Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients, 347
Daptomycin, pharmacokinetics of, in a critically ill adolescent with vancomycin-resistant enterococcal endocarditis, 694
Depression and propranolol, do randomized controlled trials always trump case reports? A second look at, 162
Desensitization strategy, intravenous linezolid administered orally: a novel, 563
Desipramine and nortriptyline, rates of in vivo methylation of, 505
Dexmedetomidine, addition of, to standard sedation regimens after cardiac surgery: an outcomes analysis, 798
Diabetes mellitus drug therapy management service, clinical impact of a pharmacist-managed, 248
Diabetes mellitus, adjunctive therapy with pramlintide in patients with type 1 or type 2, 1626
Diabetes mellitus, carvedilol versus cardioselective beta-blockers for the treatment of hypertension in patients with type 2, 1491
Diabetes mellitus, effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset, a review and pooled analysis, 1297
Diabetes mellitus, incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2, 360
Diabetes mellitus, long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2, 1388
Diabetes mellitus, management of, in hospitalized patients: efficiency and effectiveness of sliding-scale insulin therapy, 1421
Digoxin toxicity, telithromycin-induced, and electrocardiographic changes, 872
Digoxin, evaluation of a sex-based difference in the pharmacokinetics of, 44
Dipeptidyl peptidase-IV inhibitors and incretin mimetics, potential new therapies for type 2 diabetes mellitus, 360
Dipyrone-induced granulocytopenia: a case for awareness, 440
Direct thrombin inhibitors, evaluation of treatment with, in patients with heparin-induced thrombocytopenia, 461
Dobutamine, pharmacoeconomic modeling of nesiritide versus, for decompensated heart failure, 34
Docetaxel-associated epiphora, 853
Doxycycline, antibiotic selection and resistance issues with fluoroquinolones and, against bioterrorism agents, 3
Drotrecogin alfa (activated), treatment of heparin-induced thrombocytopenia with, 428
Drotrecogin alfa (activated), use of, in older patients with severe sepsis, 533
Drug screen, opiate urine, gatifloxacin interference with, 435
Drug-related hospitalizations in a tertiary care internal medicine service of a Canadian hospital: a prospective study, 1578
Dyslipidemias, key articles, guidelines, and consensus papers relative to the treatment of, 2005, 939

- E -

Editorial, higher, faster, farther, 151
Editorial, orchestrating the growth of pharmacy as a clinical profession, 1
Elderly, estimation of glomerular filtration rate in the, Cockcroft-Gault formula versus modification of diet in renal disease formula (alternative viewpoint), 1041
Elderly, potentially inappropriate drug use and health-related quality of life in the, 768
Electrocardiographic changes, telithromycin-induced digoxin toxicity and, 872
Electronic medical record flag alerts, 5-year evaluation of, for patients warranting secondary prevention of coronary heart disease, 682
Eletriptan, safety and efficacy of, in the treatment of acute migraine, 115
Endocannabinoid system, the, 218S
Endocarditis, daptomycin for the treatment of gram-positive bacteremia and infective: a retrospective case series of 31 patients, 347
Endocarditis, pharmacokinetics of daptomycin in a critically ill adolescent with vancomycin-resistant enterococcal, 694
Enfuvirtide, pharmacokinetic bioequivalence of, using a needle-free device versus standard needle administration, 1679
Enoxaparin, reactive thrombocytosis associated with, 1667
Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection, 1745
Ephedra-containing Trimspa thermogenic herbal compound in healthy volunteers, electrocardiographic and blood pressure effects of the, 1241
Epiphora, docetaxel-associated, 853
Epoetin alfa regimens, erythropoietic response to two, in critically ill patients: a pilot study, 1587
Erythema multiforme after meningitis vaccine: patient safety concerns with repeat immunization, 1658
Erythropoietic response to two epoetin alfa regimens in critically ill patients: a pilot study, 1587
Esomeprazole, effects of, on the pharmacokinetics of atazanavir and fosamprenavir in a patient with

human immunodeficiency virus infection, 511
Esophagitis, progressive, caused by Candida albicans with reduced susceptibility to caspofungin, 877

- F -

Factor VII, reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated, in patients receiving warfarin, 1091
Factor VIIa, recombinant, for refractory bleeding after cardiac surgery secondary to anticoagulation with the direct thrombin inhibitor lepirudin, 569
Fat redistribution, effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus–related, evaluated by dual-energy x-ray absorptiometry, 154
Fenofibrate therapy, effects of, on plasma ubiquinol-10 and ubiquinone-10 levels in Japanese patients with hyperlipidemia and type 2 diabetes mellitus, 447
Fever, clopidogrel-induced hepatotoxicity and, 1023
Filters, retrievable and permanent inferior vena cava: selected considerations, 1595
Fluoroquinolones and doxycycline, antibiotic selection and resistance issues with, against bioterrorism agents, 3
Food, effect of, and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers, 1060
Fosamprenavir, effects of esomeprazole on the pharmacokinetics of atazanavir and, in a patient with human immunodeficiency virus infection, 511
Fungal infections, treatment options for invasive, 55S

- G -

Gatifloxacin interference with opiate urine drug screen, 435
Gatifloxacin, anticoagulation-related outcomes in patients receiving warfarin after starting levofloxacin or, 1446
Geriatric patients with severe sepsis, use of drotrecogin alfa (activated) in, 533
Glomerular filtration rate in the elderly, estimation of, Cockcroft-Gault formula versus modification of diet in renal disease formula (alternative viewpoint), 1041
Glucose control in the intensive care unit, barriers to, 214
Glyburide, long-term safety of pioglitazone versus, in patients with recently diagnosed type 2 diabetes mellitus, 1388
Golf-inhibiting gynecomastia associated with atorvastatin therapy, 1165
Gonadotropin-releasing hormone analogs, recurrent anaphylaxis associated with, case report and review of the literature, 1811
Gram-positive bacteremia and infective endocarditis, daptomycin for the treatment of: a retrospective case series of 31 patients, 347
Granulocytopenia, dipyrone-induced: a case for awareness, 440
Growth factors, a tale of two, 443
Gynecomastia, golf-inhibiting, associated with atorvastatin therapy, 1165

- H -

Health care use, association of refill adherence and, among adults with hypertension in an urban health care system, 779
Heart failure, drug copayment and adherence in chronic, effect on cost and outcomes, 1157
Heart failure, management of acute decompensated, treatment, controversy, and future directions, 131S
Heart failure, outcomes associated with vasoactive therapy in patients with acute decompensated, 1078
Heart failure, pharmacoeconomic modeling of nesiritide versus dobutamine for decompensated, 34
Heliox, effect of, on albuterol delivery by metered-dose inhaler in pediatric in vitro models of mechanical ventilation, 1396
Heparin versus lepirudin flushes, use of, to prevent withdrawal occlusion of central venous access devices, 1262
Heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction, evaluation of bivalirudin treatment for, 452
Heparin-induced thrombocytopenia, evaluation of treatment with direct thrombin inhibitors in patients with, 461
Heparin-induced thrombocytopenia, incidence and economic implications of, in medical patients receiving prophylaxis for venous thromboembolism, 1438
Heparin-induced thrombocytopenia, lepirudin anticoagulation for, after cardiac surgery in a pediatric patient, 709
Heparin-induced thrombocytopenia, prolonged anticoagulation after discontinuation of argatroban and warfarin therapy in an obese patient with, 1806
Heparin-induced thrombocytopenia, treatment of, is there a role for bivalirudin, 229
Heparin-induced thrombocytopenia, treatment of, with drotrecogin alfa (activated), 428
Hepatitis B infection, entecavir: a new nucleoside analog for the treatment of chronic, 1745
Hepatotoxicity and fever, clopidogrel-induced, 1023
Hepatotoxicity, thalidomide-induced severe, 1018
Higher, faster, farther (editorial), 151
Highly active antiretroviral therapy modifications, high frequency of, in patients with acute or early human immunodeficiency virus infection, 674
Hormone therapy, life after the women's health initiative: evaluation of postmenopausal symptoms and use of alternative therapies after discontinuation of, 1403
Human immunodeficiency virus infection, effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with, 511
Human immunodeficiency virus infection, high frequency of highly active antiretroviral therapy modifications in patients with acute or early, 674
Human immunodeficiency virus–related fat redistribution evaluated by dual-energy x-ray

absorptiometry, effects of discontinuing stavudine or protease inhibitor therapy on, 154
Hyperbilirubinemia, amphotericin B–associated: case report and review of the literature, 1011
Hypercalcemia of malignancy, ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and, 655
Hyperglycemia management in the intensive care unit, a practical approach to, evaluation of an intensive insulin infusion protocol, 1410
Hypertension control, effectiveness of a two-part educational intervention to improve, a cluster-randomized trial, 1342
Hypertension in an urban health care system, association of refill adherence and health care use among adults with, 779
Hypertension in patients with type 2 diabetes mellitus, carvedilol versus cardioselective beta-blockers for the treatment of, 1491
Hypertension, discordant beta-blocker effects on clinic, ambulatory, resting, and exercise hemodynamics in patients with, 1255
Hypertension, factors associated with drug adherence and blood pressure control in patients with, 483
Hypertension, probable association between ziprasidone and worsening, 1352
Hypertension, randomized, double-blind, crossover comparison of amlodipine and valsartan in African-Americans with, using 24-hour ambulatory blood pressure monitoring, 889
Hyperuricemia associated with malignancy, reduced-dose rasburicase in the treatment of adults with, 242
Hypomobility ("off") episodes, update on apomorphine for the rapid treatment of, in Parkinson's disease, 840

- I, J -

Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy, 655
ICA-17043, dose-escalation study of, in patients with sickle cell disease, 1557
Idiopathic pulmonary arterial hypertension during the past 25 years, pharmacotherapy for, 68
Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration, 1501
Imatinib and its metabolite cgp74588, disposition of, in a patient with chronic myelogenous leukemia and short-bowel syndrome, 903
Immunoglobulin, pharmacokinetics of intravenous, a systematic review, 813
Immunosuppressants, factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select, 1730
Immunosuppressive therapy for acute porphyria: safety and efficacy in a patient with bone marrow failure, 1662
Inappropriate drug use and health-related quality of life in the elderly, 768
Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus, 360
Indinavir and saquinavir exposure, lack of in vivo correlation between, and cytochrome P450 3A phenotype as assessed with oral midazolam as a phenotype probe, 1051
Infectious diseases, international adoption: issues in, 1207
Influenza, combating, with antiviral therapy in the pediatric population, 95
Insulin infusion protocol, a practical approach to hyperglycemia management in the intensive care unit: evaluation of an intensive, 1410
Insulin therapy, management of diabetes mellitus in hospitalized patients: efficiency and effectiveness of sliding-scale, 1421
Intensive care unit, barriers to glucose control in the, 214
International adoption: issues in infectious diseases, 1207
Isoniazid toxicity, acute, and the need for adequate pyridoxine supplies, 1529
Itraconazole-sirolimus interaction in a hematopoietic stem cell transplant recipient, 289

- K, L -

Key articles, guidelines, and consensus papers relative to the treatment of dyslipidemias—2005, 939
Laboratory safety monitoring of ongoing drug therapy in ambulatory patients, randomized trial to improve, 619
Lamotrigine and olanzapine, lack of pharmacokinetic interaction between, in healthy volunteers, 627
Lamotrigine-induced toxic epidermal necrolysis in three patients treated for bipolar disorder, 699
Lansoprazole gastric acid suppression, inhibition of atazanavir oral absorption by, in healthy volunteers, 341
Leflunomide and warfarin interaction: case report and review of the literature, 868
Lepirudin anticoagulation for heparin-induced thrombocytopenia after cardiac surgery in a pediatric patient, 709
Lepirudin flushes, use of heparin versus, to prevent withdrawal occlusion of central venous access devices, 1262
Lepirudin, recombinant factor VIIa for refractory bleeding after cardiac surgery secondary to anticoagulation with the direct thrombin inhibitor, 569
Levofloxacin or gatifloxacin, anticoagulation-related outcomes in patients receiving warfarin after starting, 1446
Levothyroxine and raloxifene, increased thyroid-stimulating hormone levels associated with concomitant administration of, 881
Limited sampling strategy for predicting area under the concentration-time curve of mycophenolic acid in adult lung transplant recipients, 1232

Linezolid and selective serotonin reuptake inhibitors, drug interactions between, case report involving sertraline and review of the literature, 269
Linezolid and serotonin agonists, risk of serotonin syndrome with concomitant administration of, 1784
Linezolid therapy, Bell's palsy associated with, case report and review of neuropathic adverse events, 1183
Linezolid, intravenous, administered orally: a novel desensitization strategy, 563
Lipoglycopeptide antibacterial, dalbavancin: a novel, 908
Lisinopril and losartan therapy for proteinuria, acute renal failure during, 1348
Liver transplant recipients, effect of long-term tacrolimus immunosuppression on renal function in, 1433
Lorazepam for sedation, osmol gap as a surrogate marker for serum propylene glycol concentrations in patients receiving, 23
Losartan therapy for proteinuria, acute renal failure during lisinopril and, 1348
Low-molecular-weight heparin, use of, to bridge therapy in obese patients and in patients with renal dysfunction, 1479

- M -

Malaria, Plasmodium falciparum, associated with mefloquine failure in Gambia, 1526
Managed care setting, reduction of high-risk polypharmacy drug combinations in patients in a, 886
Medication-related problems in a family health center, implementation of a self-administered questionnaire to identify patients at risk for, 260
Mefloquine failure in Gambia, Plasmodium falciparum malaria associated with, 1526
Memory loss, short-term, associated with rosuvastatin, 1190
Meningitis vaccine, erythema multiforme after, patient safety concerns with repeat immunization, 1658
Metabolic syndrome and cardiometabolic risk: scope of the problem and current standard of care, 3S
Metabolic syndrome supplement, introduction, 207S
Metabolic syndrome treatment strategies, 222S
Metabolic syndrome, challenges associated with, 209S
Metered-dose inhaler, effect of heliox on albuterol delivery by, in pediatric in vitro models of mechanical ventilation, 1396
Methamphetamine abuse, clinical effects and management of, 1148
Methicillin-resistant Staphylococcus aureus infections, management of community-associated, in children, 1758
Methicillin-resistant Staphylococcus aureus pneumonia, potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with, 539
Methylation of desipramine and nortriptyline, rates of in vivo, 505
Midazolam as a phenotype probe, lack of in vivo correlation between indinavir and saquinavir exposure and cytochrome P450 3A phenotype as assessed with oral, 1051
Migraine prevention, topiramate for, 375
Migraine, safety and efficacy of eletriptan in the treatment of acute, 115
Minocycline for short-term neuroprotection, 515
Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future, 129
Mycobacterium szulgai in a patient with advanced acquired immunodeficiency syndrome: an unusual pathogen with unusual multidrug resistance, 1646
Mycophenolic acid, limited sampling strategy for predicting area under the concentration-time curve of, in adult lung transplant recipients, 1232
Myocardial infarction, improving pharmacotherapy after, by group academic detailing using feedback data on a patient level, 254
Myocardial infarction, nonsteroidal antiinflammatory drugs and acute, in patients with no major risk factors, 1379
Myocardial infarction, ST-segment–elevation, guidelines and the challenge of real-world patient care, 115S

- N -

Nausea and vomiting during pregnancy, treatment options for, 1273
Nausea assessment tool, development and validation of the pediatric, for use in children receiving antineoplastic agents, 1221
Needle-free device versus standard needle administration, pharmacokinetic bioequivalence of enfuvirtide using a, 1679
Neonate with renal disease, nesiritide therapy in a term, 281
Neonates, therapeutic levels of intravenous procainamide in, a retrospective assessment, 1687
Nesiritide bolus dose in a pediatric patient, administration of a large: case report and review of nesiritide use in pediatrics, 277
Nesiritide therapy in a term neonate with renal disease, 281
Nesiritide versus dobutamine for decompensated heart failure, pharmacoeconomic modeling of, 34
Nesiritide: harmful or harmless?, 1465
Neuroleptic malignant syndrome, olanzapine-associated, 1180
Neurologic emergencies, the challenge of blood pressure management in, 123S
Neuropathic pain, ziconotide infusion for severe chronic pain: case series of patients with, 395
Neuroprotection, minocycline for short-term, 515
Neurotoxicity and seizures, management of star fruit–induced, in a patient with chronic renal failure, 143
Neurotoxicity, cefepime, case report, pharmacokinetic considerations, and literature review, 1169

Neutropenia, design of clinical trials of empiric antifungal therapy in patients with persistent febrile: considerations and critiques, 47S
Nifedipine, bezoar formation requiring endoscopic removal after intentional overdose of extended-release, 1802
Nitrofurantoin-induced pulmonary toxicity, recurrent acute, 713
Nonsteroidal antiinflammatory drugs and acute myocardial infarction in patients with no major risk factors, 1379
Nonsteroidal antiinflammatory drugs, interaction between selective serotonin reuptake inhibitors and, review of the literature, 1307
Nortriptyline, rates of in vivo methylation of desipramine and, 505

- O -

Obese patient with heparin-induced thrombocytopenia, prolonged anticoagulation after discontinuation of argatroban and warfarin therapy in an, 1806
Obese patients and in patients with renal dysfunction, use of low-molecular-weight heparin to bridge therapy in, 1479
Off-label drug therapies, the major role of clinicians in the discovery of, 323
Olanzapine, lack of pharmacokinetic interaction between lamotrigine and, in healthy volunteers, 627
Olanzapine-associated neuroleptic malignant syndrome, 1180
Opiate urine drug screen, gatifloxacin interference with, 435
Osmol gap as a surrogate marker for serum propylene glycol concentrations in patients receiving lorazepam for sedation, 23
Osteoporosis, bone metastases, and hypercalcemia of malignancy, ibandronate, an experimental intravenous bisphosphonate for, 655
Osteoporosis, examining the relationship between bone mineral density and fracture risk reduction during pharmacologic treatment of, 104
Overactive bladder, pharmacoeconomic evaluation of antimuscarinic agents for the treatment of, 1694
Oxygen therapeutics: oxygen delivery without blood, 1453

- P -

Pandemics, avian influenza A (H5N1), and a strategy for pharmacists, 312
Parkinson's disease, update on apomorphine for the rapid treatment of hypomobility ("off") episodes in, 840
Patient withdrawal, effect of, on a study evaluating pharmacist management of hypertension, 1565
Pediatric nausea assessment tool, development and validation of the, for use in children receiving antineoplastic agents, 1221
Pediatric patient, administration of a large nesiritide bolus dose in a, case report and review of nesiritide use in pediatrics, 277
Pediatric patients receiving hematopoietic stem cell transplants, disposition of two oral formulations of cyclosporine in, 15
Pediatric population, combating influenza with antiviral therapy in the, 95
Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy, 641
Penicillin, severe serum sickness reaction to oral and intramuscular, 705
Percutaneous coronary interventions, newer pharmacotherapy in patients undergoing, a guide for pharmacists and other health care professionals, 1537
Percy medicine, salicylate toxicity associated with administration of, in an infant, 403
Peripheral arterial occlusion, comparative safety and efficacy of urokinase and recombinant tissue plasminogen activator for, a meta-analysis, 51
P-glycoprotein, role of, in statin drug interactions, 1601
Pharmaceutical education, changing the structure of, to require doctor of pharmacy and postgraduate residency education and training, 587
Pharmacist management of hypertension, effect of patient withdrawal on a study evaluating, 1565
Pharmacist-managed blood pressure program, coronary artery disease and hypertension: outcomes of a, 1333
Pharmacist-managed diabetes mellitus drug therapy management service, clinical impact of a, 248
Pharmacists, workplace-based cardiovascular risk management by community, impact on blood pressure, lipid levels, and weight, 1511
Pharmacodynamic concepts into clinical practice, application of antimicrobial, focus on beta-lactam antibiotics: Society of Infectious Diseases Pharmacists, 1320
Pharmacotherapy board certification examination preparatory manual, investigating the potential influence of established multiple-choice test-taking cues on item response in a: a pilot study, 558
Pharmacotherapy specialty certification examination, preparation for the, are question cues enough? (alternative viewpoints), 1675
Pharmacy as a clinical profession, orchestrating the growth of (alternative viewpoints), 1047
Pharmacy as a clinical profession, orchestrating the growth of (editorial), 1
Pharmacy staffing, clinical pharmacy services, and adverse drug reactions in United States hospitals, 735
Pharmacy, clinical maturity in (editorial), 594
Pharmacy's vision of the future, ACCP position statement: American College of Clinical, post-graduate pharmacy residency training as a prerequisite for direct patient care practice, 722
Pioglitazone versus glyburide, long-term safety of, in patients with recently diagnosed type 2 diabetes mellitus, 1388
Pioglitazone, implications of rosiglitazone and, on cardiovascular risk in patients with type 2 diabetes

mellitus, 168
Piperacillin-tazobactam shortage, impact of a, on antimicrobial prescribing and the rate of vancomycin-resistant enterococci and Clostridium difficile infections, 61
Pituitary tumors, atypical antipsychotics and, a pharmacovigilance study, 748
Pleiotropy, statin-associated, possible beneficial effects beyond cholesterol reduction, 85S
Pneumonia, optimizing antibiotic treatment for ventilator-associated, 204
Pneumonia, potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus, 539
Polypharmacy drug combinations, reduction of high-risk, in patients in a managed care setting, 886
Porphyria, immunosuppressive therapy for acute, safety and efficacy in a patient with bone marrow failure, 1662
Postmenopausal symptoms and use of alternative therapies after discontinuation of hormone therapy, life after the women's health initiative: evaluation of, 1403
Potential interactions between prescription drugs and complementary and alternative medicines among patients in the emergency department, 634
Povidone-iodine–induced burn: case report and review of the literature, 1641
Pramlintide, adjunctive therapy with, in patients with type 1 or type 2 diabetes mellitus, 1626
Pregnancy, treatment options for nausea and vomiting during, 1273
Procainamide, therapeutic levels of intravenous, in neonates: a retrospective assessment, 1687
Propranolol and depression, do randomized controlled trials always trump case reports? A second look at, 162
Propylene glycol concentrations, osmol gap as a surrogate marker for serum, in patients receiving lorazepam for sedation, 23
Prostate cancer chemoprevention, update on, 353
Prostate cancer, chemoprevention in (alternative viewpoints), 1533
Protease inhibitor therapy, effects of discontinuing stavudine or, on human immunodeficiency virus–related fat redistribution evaluated by dual-energy x-ray absorptiometry, 154
Proteinuria, acute renal failure during lisinopril and losartan therapy for, 1348
Pulmonary arterial hypertension, pharmacotherapy for idiopathic, during the past 25 years, 68
Pulmonary distribution, potential impact of vancomycin, on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia, 539
Pulmonary toxicity, recurrent acute nitrofurantoin-induced, 713
Pyridoxine supplies, acute isoniazid toxicity and the need for adequate, 1529

- Q, R -

Quercetin, effect of, on the plasma and intracellular concentrations of saquinavir in healthy adults, 1255
Quetiapine overdose, mental status change, myoclonus, electrocardiographic changes, and acute respiratory distress syndrome induced by, 578
Raloxifene, increased thyroid-stimulating hormone levels associated with concomitant administration of levothyroxine and, 881
Ranitidine, effect of food and, on saquinavir pharmacokinetics and gastric pH in healthy volunteers, 1060
Ranolazine, a novel agent for chronic stable angina, 135
Rasburicase 6 mg, single-dose, in the management of tumor lysis syndrome in adults, 806
Rasburicase, reduced-dose, in the treatment of adults with hyperuricemia associated with malignancy, 242
Recombinant tissue plasminogen activator, comparative safety and efficacy of urokinase and, for peripheral arterial occlusion: a meta-analysis, 51
Refill adherence, association of, and health care use among adults with hypertension in an urban health care system, 779
Renal disease, sevelamer therapy for pediatric end-stage, 410
Renal dysfunction, use of low-molecular-weight heparin to bridge therapy in obese patients and in patients with, 1479
Renal failure, acute, during lisinopril and losartan therapy for proteinuria, 1348
Renal function in liver transplant recipients, effect of long-term tacrolimus immunosuppression on, 1433
Renal transplantation, rabbit antithymocyte globulin induction therapy in adult, 1771
Research in clinical pharmacy, ACCP white paper: the state of science and, 1027
Research, complementary and alternative medicine use among individuals participating in, implications for research and practice, 1794
Residency education and training, changing the structure of pharmaceutical education to require doctor of pharmacy and postgraduate, 587
Residency training as a prerequisite for direct patient care practice, ACCP position statement: American College of Clinical Pharmacy's vision of the future: postgraduate pharmacy, 722
Retrievable and permanent inferior vena cava filters: selected considerations, 1595
Role of the pharmacist, metabolic syndrome, 227S
Rosiglitazone and pioglitazone, implications of, on cardiovascular risk in patients with type 2 diabetes mellitus, 168
Rosuvastatin, effect of, compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting, 469
Rosuvastatin, short-term memory loss associated with, 1190
Royal jelly and warfarin interaction, 583

- S -

Salicylate toxicity associated with administration of Percy medicine in an infant, 403
Salvinorin A content in five salvia divinorum herbal products, analysis of the psychoactive terpenoid, 1268
Saquinavir exposure, lack of in vivo correlation between indinavir and, and cytochrome P450 3A phenotype as assessed with oral midazolam as a phenotype probe, 1051
Saquinavir in healthy adults, effect of quercetin on the plasma and intracellular concentrations of, 1255
Saquinavir pharmacokinetics, effect of food and ranitidine on, and gastric pH in healthy volunteers, 1060
Science and research in clinical pharmacy, ACCP white paper: the state of, 1027
Scientific collaboration results in higher citation rates of published articles, 759
Selective serotonin reuptake inhibitors and nonsteroidal antiinflammatory drugs, interaction between, review of the literature, 1307
Selective serotonin reuptake inhibitors, drug interactions between linezolid and, case report involving sertraline and review of the literature, 269
Sepsis, use of drotrecogin alfa (activated) in older patients with severe, 533
Serotonin agonists, risk of serotonin syndrome with concomitant administration of linezolid and, 1784
Serotonin syndrome, risk of, with concomitant administration of linezolid and serotonin agonists, 1784
Sertraline, drug interactions between linezolid and selective serotonin reuptake inhibitors: case report involving, and review of the literature, 269
Serum sickness reaction, severe, to oral and intramuscular penicillin, 705
Sevelamer therapy for pediatric end-stage renal disease, 410
Severe chronic pain, ziconotide infusion for: case series of patients with neuropathic pain, 395
Sex-based difference, evaluation of a, in the pharmacokinetics of digoxin, 44
Sexual issues, counseling patients about, 1608
Sickle cell disease, dose-escalation study of ICA-17043 in patients with, 1557
Simvastatin-associated pancreatitis, a case of, and review of statin-associated pancreatitis, 414
Sirolimus-itraconazole interaction in a hematopoietic stem cell transplant recipient, 289
Skin necrosis, atypical warfarin-induced, 1175
Society of Infectious Diseases Pharmacists, Clostridium difficile–associated disease: an emerging threat to patient safety: insights from the, 299
Society of Infectious Diseases Pharmacists: application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: 1320
Staphylococcus aureus infections in children, management of community-associated methicillin-resistant, 1758
Star fruit–induced neurotoxicity and seizures in a patient with chronic renal failure, management of, 143
Statin drug interactions, role of p-glycoprotein in, 1601
Statin withdrawal: clinical implications and molecular mechanisms, 1288
Statin-associated pancreatitis, a case of simvastatin-associated pancreatitis and review of, 414
Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction, 855
Statins and clopidogrel, combination of: a hypothetical interaction or therapeutic dilemma, 388
Stavudine or protease inhibitor therapy, effects of discontinuing, on human immunodeficiency virus–related fat redistribution evaluated by dual-energy x-ray absorptiometry, 154
Stimulants, illicit use of specific prescription, among college students: prevalence, motives, and routes of administration, 1501
Stroke, anticoagulation strategies for treatment of ischemic, and antiphospholipid syndrome: case report and review of the literature, 1518
Stroke, high prevalence of previous antiplatelet drug use in patients with new or recurrent ischemic: Buffalo metropolitan area and Erie county stroke study, 493
Subarachnoid hemorrhage, cerebral vasospasm after aneurysmal, an overview of pharmacologic management, 182
Sulfonamide allergies and outcomes related to use of potentially cross-reactive drugs in hospitalized patients, 551

- T -

Tacrolimus immunosuppression, effect of long-term, on renal function in liver transplant recipients, 1433
Tacrolimus, factors affecting the apparent clearance of, in Korean adult liver transplant recipients, 1069
Telithromycin-induced digoxin toxicity and electrocardiographic changes, 872
Test-taking cues, investigating the potential influence of established multiple-choice, on item response in a Pharmacotherapy board certification examination preparatory manual: a pilot study, 558
Thalidomide-induced severe hepatotoxicity, 1018
Thiazolidinedione use, implications of, and cardiovascular risk: is it all about the sugar (alternative viewpoint), 1049
Thrombocytopenia, abciximab-associated, after previous tirofiban-related thrombocytopenia, 423
Thrombocytopenia, lepirudin anticoagulation for heparin-induced, after cardiac surgery in a pediatric patient, 709
Thrombocytosis, reactive, associated with enoxaparin, 1667
Thromboembolism, prophylaxis against venous, in acutely ill medical patients: an observational study,

1086
Thyroid function, possible effect of, on anticoagulant response to unfractionated heparin, 285
Thyroid-stimulating hormone levels, increased, associated with concomitant administration of levothyroxine and raloxifene, 881
Tigecycline: first of a new class of antimicrobial agents, 1099
Tolterodine and warfarin, probable interaction between, 719
Topiramate for migraine prevention, 375
Toxic epidermal necrolysis, lamotrigine-induced, in three patients treated for bipolar disorder, 699
Tramadol-warfarin interaction, successful anticoagulation and continuation of tramadol therapy in the setting of a, 1654
Treprostinil for the treatment of pulmonary arterial hypertension in patients with New York Heart Association class II–IV symptoms (alternative viewpoints), 1203
Trimspa thermogenic herbal compound in healthy volunteers, electrocardiographic and blood pressure effects of the ephedra-containing, 1241
Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma (alternative viewpoints), 1205
Tumor lysis syndrome in adults, single-dose rasburicase 6 mg in the management of, 806

- U, V -

Ubiquinol-10 and ubiquinone-10 levels, effects of fenofibrate therapy on plasma, in Japanese patients with hyperlipidemia and type 2 diabetes mellitus, 447
Unfractionated heparin, possible effect of thyroid function on anticoagulant response to, 285
Urine drug screen, opiate, gatifloxacin interference with, 435
Urokinase and recombinant tissue plasminogen activator, comparative safety and efficacy of, for peripheral arterial occlusion: a meta-analysis, 51
Vaccine, erythema multiforme after meningitis, patient safety concerns with repeat immunization, 1658
Valsartan, randomized, double-blind, crossover comparison of amlodipine and, in African-Americans with hypertension using 24-hour ambulatory blood pressure monitoring, 889
Vancomycin pulmonary distribution, potential impact of, on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia, 539
Vancomycin-resistant enterococcal endocarditis, pharmacokinetics of daptomycin in a critically ill adolescent with, 694
Vancomycin-resistant enterococci and Clostridium difficile infections, impact of a piperacillin-tazobactam shortage on antimicrobial prescribing and the rate of, 61
Vasoactive therapy, outcomes associated with, in patients with acute decompensated heart failure, 1078
Vasopressin, evolving role of, in the treatment of cardiac arrest, 828
Vasospasm, cerebral, after aneurysmal subarachnoid hemorrhage: an overview of pharmacologic management, 182
Vena cava filters, retrievable and permanent inferior: selected considerations, 1595
Ventilator-associated pneumonia, optimizing antibiotic treatment for, 204
Vomiting during pregnancy, treatment options for nausea and, 1273

- W, X, Y, Z -

Warfarin and cranberry juice, interaction between, 1314
Warfarin and royal jelly interaction, 583
Warfarin interaction, successful anticoagulation and continuation of tramadol therapy in the setting of a tramadol-, 1654
Warfarin therapy, prolonged anticoagulation after discontinuation of argatroban and, in an obese patient with heparin-induced thrombocytopenia, 1806
Warfarin, anticoagulation-related outcomes in patients receiving, after starting levofloxacin or gatifloxacin, 1446
Warfarin, effect of carbamazepine initiation and discontinuation on antithrombotic control in a patient receiving, case report and review of the literature, 1650
Warfarin, leflunomide and, interaction: case report and review of the literature, 868
Warfarin, probable interaction between tolterodine and, 719
Warfarin, reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving, 1091
Warfarin-induced skin necrosis, atypical, 1175
Wind, against the (editorial), 597
Women's health initiative, life after the, evaluation of postmenopausal symptoms and use of alternative therapies after discontinuation of hormone therapy, 1403
Ziconotide infusion for severe chronic pain: case series of patients with neuropathic pain, 395
Ziprasidone and worsening hypertension, probable association between, 1352